Initial total daily insulin setting for user onboarding

Description

BACKGROUND

Many people are diagnosed with Type 1 diabetes mellitus (TIDM) each year, according to the Food and Drug Administration. These patients may require insulin pumps and may desire to utilize an automatic insulin delivery (AID) system. However, the potential new users of AID systems have no pump parameters and no historical total daily insulin (TDI) data at all and nearly 50% of the new users will enter into honeymoon phase, where patients' insulin needs vary rapidly. TDI is a total amount of insulin delivered to a user in a day. It is based on how much insulin a user needs for the day. The honeymoon period may last up to six months, or as long as it takes the insulin-producing cells of the pancreas to die.

TDI of newly diagnosed patient may be determined in a number of way. Presently, initialization of TDI for a newly diagnosed diabetic patient is based on: 1) weight only; and 2) weight, glycated hemoglobin (HbA1C) (which is used for manual insulin delivery) and ketones (For example, TDI may be determined using a formula such as TDI=(−38)+1.4*weight (kg)+0.17*HbA1C (in mmol/mol)+4.3*ketones (mmol/L)). When weight alone is used, children with moderate hyperglycemia but without ketonuria or acidosis may be started with a single daily subcutaneous injection of 0.3-0.5 u/kg of intermediate-acting insulin alone. Children with hyperglycemia and ketonuria but without acidosis or dehydration may be started on a TDI established using a formulation of 0.5-0.7 u/kg of intermediate-acting insulin.

The TDI determined in this manner is only a generalization and may not satisfy needs of all new patients. It would be beneficial and advantageous to have a system, a device and/or a technique for optimizing a TDI for newly-diagnosed diabetic uses who may desire to use an automatic insulin delivery system.

SUMMARY

Disclosed is a non-transitory computer readable medium embodied with programming code executable by a processor, and the processor when executing the programming code is operable to perform functions, and a process. A processor may be operable to receive a request via a graphical user interface to establish initial settings for an automatic insulin delivery device. An input of at least one physical characteristic of a user may be received. An adjusted total daily insulin factor usable to calculate a total daily insulin dosage may be determined. The adjusted total daily insulin factor may be a total daily insulin per unit of the user's weight reduced by a reduction factor. A comparison result generated by comparing the adjusted total daily insulin factor to a maximum algorithm delivery threshold. A total daily insulin dosage may be set based on the comparison result. Blood glucose measurement values may be obtained over a period of time. Based on the obtained blood glucose measurement values, a level of glycated hemoglobin of a user may be determined. In response to the determined level of glycated hemoglobin, the set total daily insulin dosage may be modified to provide a modified total daily insulin dosage. A control signal may be output that includes the modified total daily insulin dosage instructing a controller of a drug delivery device to actuate delivery of insulin according to the modified total daily insulin dosage.

Also disclosed is a device that includes a processor, a memory, a wireless communication device and an artificial pancreas application executable by the processor. The processor may be operable to execute programming code and applications including the artificial pancreas application. The memory may be coupled to the processor and operable to store programming code, an artificial pancreas application and data. The wireless communication device may be operable to wirelessly communicate with a paired device and communicatively coupled to the processor. The artificial pancreas application may be executable by the processor, and the processor, when executing the artificial pancreas application, is operable to perform functions. The functions may include attaining information associated with a user. An adjusted total daily insulin factor may be established. The processor may determine whether the adjusted total daily insulin factor exceeds a maximum algorithm delivery threshold. In response to a result of the determination, a total daily insulin dosage using the attained information may be set. The processor may obtain blood glucose measurement values over a period of time. Based on the obtained blood glucose measurement values, the processor may determine a level of glycated hemoglobin of a user. In response to the determined level of glycated hemoglobin, the set total daily insulin dosage may be modified to provide a modified total daily insulin dosage. A control signal may be output that includes the modified total daily insulin dosage instructing a controller to actuate delivery of insulin according to the modified total daily insulin dosage.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates an example of a process for determining an initial total daily insulin dosage related to a diabetes treatment program of a newly-diagnosed user that is onboarding.

FIG. 2 illustrates another example of a process for determining an initial total daily insulin dosage related to a diabetes treatment program of a newly-diagnosed user that is onboarding.

FIG. 3 illustrates a functional block diagram of drug delivery system suitable for implementing the example processes and techniques described herein including those described with reference to FIGS. 1 and 2.

FIG. 4 illustrates a graphic including results of example functions usable in the determination of an initial total daily insulin with respect to the example process of FIG. 1.

FIG. 5 illustrates a graphic including results of example functions usable in the determination of an initial total daily insulin with respect to the example process of FIG. 2.

DETAILED DESCRIPTION

An example provides a process that may be used with any additional algorithms or computer applications that manage blood glucose levels and insulin therapy. Such algorithms may be referred to as an “artificial pancreas” algorithm-based system, or more generally, an artificial pancreas (AP) application or automatic insulin delivery (AID) algorithm, that provides automatic delivery of an insulin based on a blood glucose sensor input, such as that received from a CGM or the like. In an example, the artificial pancreas (AP) application when executed by a processor may enable a system to monitor a user's glucose values, determine an appropriate level of insulin for the user based on the monitored glucose values (e.g., blood glucose concentrations or blood glucose measurement values) and other information, such as user-provided information, such as carbohydrate intake, exercise times, meal times or the like, and take actions to maintain a user's blood glucose value within an appropriate range. The appropriate blood glucose value range may be considered a target blood glucose value of the particular user. For example, a target blood glucose value may be acceptable if it falls within the range of 80 mg/dL to 120 mg/dL, which is a range satisfying the clinical standard of care for treatment of diabetes. Alternatively, in addition, an AP application (or AID algorithm) as described herein may be able to establish a target blood glucose value more precisely and may set the target blood glucose value at, for example, 110 mg/dL, or the like. As described in more detail with reference to the examples of FIGS. 1-5, the AP application (or AID algorithm) may utilize the monitored blood glucose measurement values and other information to determine, or the like.

The total daily insulin (TDI) described in the following description is intended as an initialization input into an automatic insulin delivery system that utilizes a closed-loop control operation and is not intended for use in open-loop control operation.

Typically, persons diagnosed with diabetes, such as Type 1, are suffering from a failure of their pancreas to produce enough insulin for their bodies to properly regulate blood glucose levels. The failure of the pancreas to produce enough insulin may be due the dying of cells of the pancreas and not being regenerated. As the cells of the pancreas die, and the amount of insulin produced by the remaining pancreas cells diminishes, a point is reached where it is recommended that the user begin receiving supplemental insulin. This time period as the pancreatic cells die off, and the user may become dependent on the supplemental insulin is referred to as the “honeymoon period.” A “honeymoon period” may last, in some instances, 6-18 months given the degree of failure of the user's pancreas and the time of the user's initial diabetes diagnosis. Of course, the honeymoon period may be shorter or longer for each individual user as there is no set time period for pancreatic failure. A measurement of a user's insulin dose adjusted glycated hemoglobin (HbA1c), which may be abbreviated as IDAA1c, may be used to determine whether the user is still within the “honeymoon period,” or not. In addition, the AP application or AID algorithm may determine that a user is requiring additional insulin over time as the pancreas fails.

In general, an automatic insulin delivery (AID) system can incorporate a variety of methods to 1) calculate the initial TDI based on linear relationship between TDI and weight. 2) An advantage of the described techniques and devices it that by adjusting TDI in consideration of the impact of the particular user's honeymoon phase allows the respective users to enter into closed loop systems without need for pre-existing insulin settings.

Due to the complicated and dynamic nature of the human body's response to insulin users may end up in a hypoglycemic or hyperglycemic state after being treated with insulin therapy. This outcome is undesirable for many reasons: hypoglycemia creates an immediate risk of a severe medical event (such as a seizure, a coma, or a death) while hyperglycemia creates long term negative health effects as well as the risk of ketoacidosis. Whether a person ends up in one of these states depends on a very complicated combination of many factors and sources of error.

Individuals affected with diabetes have a plethora of complicated decisions to make throughout the day to ensure a user is providing themselves with adequate insulin therapy. An automatic insulin delivery system that utilizes algorithms and/or an artificial pancreas (AP) application is operable to make many insulin delivery and insulin therapy-related decisions for a user so that the user can live their lives as close to the average non-diabetic individual as possible. In order to assist users (including new users) with making the many insulin delivery and insulin therapy-related decisions, the AP algorithm may generate alarms and notifications via a personal diabetes management (PDM) device.

In an example, an AID algorithm within any AID system may utilize the user's initial TDI to determine starting insulin delivery settings, and as time passes and additional data regarding the new user's condition is collected (for example from a continuous glucose monitor or the like), the AID algorithm may be operable to modify the starting (or initial) insulin delivery settings.

Examples of a process for initially setting insulin delivery and modifying the stating insulin delivery settings and devices for implementing a computer application are described with reference to the figures.

FIG. 1 illustrates an example of a process for initially setting insulin doses related to a diabetes treatment program. The process 100 generates a total daily insulin dosage that is usable as an input into an artificial pancreas application in a closed-loop system. In the example process 100, a personal diabetes management device executing an artificial pancreas application or automatic insulin delivery (AID) algorithm in a closed-loop system be initially launched in response to a request to begin an initial dose setting process for newly-diagnosed users. The initial dosing setting process may also be referred to as “on-boarding.”

In the example process 100 of FIG. 1, the artificial pancreas (AP) application or AID algorithm may be operable to, in response to the initial launch (i.e., first time the application is opened on a user device or used by a first-time (i.e., new) user) or the request to begin the initial dose setting process, the artificial pancreas (AP) application or AID algorithm executing on a processor may, for example, set a default initial setting for determining total daily insulin (105). For example, the AID algorithm or AP application executing on a processor may calculate the user's default initial TDI using a relationship between TDI and weight, such as

TDI=0.53 u/kg*weight in kg,

where 0.53 is an insulin coefficient that may be based on historical clinical data for a population of newly-diagnosed diabetics, typical clinical guidance by endocrinologists as heuristic rules of thumb that provide reasonable initial glucose control, or the like.

The above value may be determined based on an assumption that a linear relationship exists between a user's weight and a user's TDI and that all user's on-boarding are in the honeymoon phase to minimize risk of hypoglycemia.

The artificial pancreas (AP) application or AID algorithm may be further operable to respond to the request or initial launch by causing a prompt to be generated and presented on a graphical user interface of a display of the personal diabetes management device (shown and described with reference to another figure). The artificial pancreas (AP) application or AID algorithm may be further operable to generate as part of the graphical user interface prompts requesting input of at least one physical characteristic of the user beginning the on-boarding process. In the process 100 example of FIG. 1, the at least one physical characteristic received as an input to the graphical user interface may be a weight of the user (110). Inputs in addition to a user's weight may also be received as inputs. For example, inputs, such as gender, age, height, body mass index, level of physical fitness, date of diagnosis as a diabetic, or the like may be received via the graphical user interface and may be stored in a memory (not shown in this example).

At 120, in response to the input of the at least one physical characteristic, the AP application or AID algorithm may execute logic to determine an adjusted total daily insulin factor (i.e., TDI/kg*(1−Reduction Proportion)). The process at 120 aims to optimize the TDI setting to minimize a user's risk of hypoglycemia and hyperglycemia. The adjustment is based on an expectation that the new user still has a portion of their pancreas functioning to produce insulin (i.e., the user is still in the honeymoon phase). Based on the assumption that every newly diagnosed user is in honeymoon phase, the process 100 at step reduces the TDI per kg by a certain proportion. In the example, the adjusted TDI factor may be equal to:

Adjusted TDI factor=0.53 u/kg*(1−X),

where X is a TDI reduction proportion.

In an example, the reduction proportion may be based on a result of an evaluation performed in response to a request sent to a server. The reduction proportion may be determined using various methods. In a specific example, one or more cost functions may be defined to determine the reduction proportion of TDI per kg. The respective cost functions may be based on a high blood glucose index (HBGI) and a low blood glucose index (LBGI) that are selected to balance both hypoglycemic and hyperglycemic risk based on the expected overdose or underdose when utilizing the adjusted TDI factor versus actual clinical data (which may be used in an open-loop calculation or when a user is no longer considered “newly-diagnosed” (e.g., 6-18 months). The respective cost functions may be:

1) BGI_3h=Cost (accumulated insulin dose)=mean (HBGI or LBGI [3 hours out of 24 hours])
- 2) BGI_basal=Cost (basal insulin)=mean (HBGI or LBGI)
- 3) BGI_peak=Cost (insulin peak time)=mean (HBGI or LBGI [1.5 hours out of 24 hours])
  
  Where HBGI and LBGI may be calculated, for example, by the following logic:

LBGI = 0;

HBG1 = 0;

Glucose_new= 1.509 * ((log(Glucose_current)){circumflex over ( )}1.084 − 5.381);

If Glucose_current< 112.5 mg/dL:

LBGI = 10 * Glucose_new{circumflex over ( )}2

Else:

HBGI = 10 * Glucose_new{circumflex over ( )}2

Either HBGI or LBGI may remain at 0 depending on the value of the current glucose for which the risk is assessed. The non-zero value is utilized to calculate the cost. In other examples, values of HBGI or LBGI may be chosen or calculated based on selected relative risks of hyperglycemia and hypoglycemia.

FIG. 4 shows an example of results of the three cost functions suitable for use with the example processes of FIG. 1. FIG. 4 illustrates examples of 3 different cost functions. The top (or upper) cost function curve (labeled 410) is the BGI_3h cost function that may represent the cost of accumulated insulin doses and be based on an HGBI or LGBI over 3 hours out of 24 hours. From the curve 410 and table (bottom) row 411, the BGI_3h cost function example has a minimum cost at approximately 24.36, which corresponds to an approximate 50% TDI reduction portion. The center cost function curve (labeled 420) is the BGI_basal cost function that may represent the cost of basal insulin doses and be based on a mean value of HGBI or LGBI. From the curve 420 and table (middle) row 421, the BGI_basal cost function has a minimum cost at approximately 12.52, which corresponds to an approximate 50% TDI reduction portion. Meanwhile, the bottom (or lowest) cost function curve (labeled 430) is the BGI_peak cost function that may represent the cost of the occurrence of insulin peak time and be based on a mean value of HGBI or LGBI at approximately 1.5 hours after insulin delivery within a 24 hour period. From the curve 430 and table (top) row 431, the BGI_peak cost function has a minimum cost at approximately 8.74, which also corresponds to an approximate 45% TDI reduction portion. The table below the respective cost function curves includes a BGI_Peak row labeled 431, a BGI_3h row labeled 411, and a BGI_basal row labeled 421. Based on the output of the three cost functions, the TDI reduction proportion X may be selected to be approximately 50%. The approximately 50% value may be based on a mean value between the three cost functions (48.333%, which may round up to 50%), a majority vote where 2 out of the 3 curves indicated a 50% TDI reduction proportion, or some other selection scheme or calculation (e.g., other than averaging and rounding) may be used. In some examples, the adjusted total daily insulin factor includes an insulin coefficient, such as 0.53, 0.50 or the like. While the foregoing cost functions were explained in detail, other cost functions may be used.

Alternatively, the cost functions may be based on a weighted mean squared error (MSE) of overdose and underdose compared to the true TDI, which also balances both hypoglycemia risk and hyperglycemia risk when utilizing the adjusted TDI factor versus actual clinical data. The respective cost functions may be formulated as:

$Cost = \frac{1}{n + m} (\sum_{i = 1}^{n} w_{1} * {({TDI}_{overdose} - {TDI}_{true})}^{2} + \sum_{j = 1}^{m} w_{2} * {({TDI}_{underdose} - {TDI}_{true})}^{2}),$

where n is the number of overdosed cases and m is the number of underdosed TDI cases, and w₁and w₂are the weights to balance the hypoglycemia risk and hyperglycemia risk, respectively.

Returning to the example of FIG. 1, the process 100 at 120 may determine an adjusted total daily insulin factor usable to calculate a user's total daily insulin dosage. The adjusted total daily insulin factor may be illustrated in the formula: Adjusted TDI/kg=A*TDI/kg*(1−Reduction Proportion), where A is an insulin coefficient. The reduction proportion of an adjusted total daily insulin factor may be identified from evaluating cost functions as described above, using clinical data gathered by health organizations, or other sources of insulin history. In the example, the AP application or the AID algorithm may send a message to a server (shown in another example), requesting downloading of the one or more cost functions to a personal diabetes management device. In an alternative example, the AP application or the AID algorithm may send a request to a server, wherein the request includes either an age of a user, a weight of the user, or both for input into one or more cost functions. The server may be operable to input the either the age of the user, the weight of the user, or both into one or more cost functions. The results of the cost function may determine a minimum value that is used to determine a reduction proportion. The AP application or AID algorithm may receive the reduction proportion. The reduction proportion may be applied to the adjusted total daily insulin factor and as a result, the reduction proportion causes a reduction in the set total daily insulin dosage.

The AP application or AID algorithm may have initially set an upper bound for a maximum algorithm delivery threshold. In the example process 100, the maximum algorithm delivery threshold may be set, for example, 0.5 u/kg/day (where u is units of insulin, kg is kilograms, day is a unit of time). In an example, the maximum algorithm delivery threshold may be approximately the maximum amount of insulin that either the AP application or AID algorithm may instruct a drug delivery device to deliver to the newly-diagnosed user. For example, the maximum algorithm delivery threshold may be referred to as the approximate maximum because in some instances, the maximum amount of insulin may be relaxed (e.g., increased) or constrained (e.g., decreased) by the AP application or AID algorithm based on detected conditions of the user and historical data.

At 130, the adjusted total daily insulin factor calculated at 120 may be compared to the maximum algorithm delivery threshold. For example, the inequality may be used to determine a result for the TDI setting:

Adjusted TDI factor>maximum algorithm daily threshold (e.g., 0.5 u/kg/day).

Should the result, at 130, of the inequality be NO, the adjusted TDI factor (with the reduction proportion) is not greater than the maximum algorithm daily threshold, the process 100 may proceed to 140. For example, the AP application or AID algorithm may determine that the comparison result indicates that the adjusted total daily insulin factor is less than the maximum algorithm delivery threshold, which causes the process 100 to proceed to 140. At 140, the AP application or the AID algorithm executed by the processor may set the TDI for delivery of insulin to the user using the adjusted TDI factor (with the reduction proportion). For example, the AP application or the AID algorithm may calculate the set total daily insulin dosage using the adjusted total daily insulin factor and the weight of the user.

Conversely, at 130, if the result of the inequality is YES, the adjusted TDI factor (with the reduction proportion) is greater than the maximum algorithm daily threshold, the process 100 may proceed to 150. For example, at 130, the AP application or AID algorithm may determine that the comparison result indicates that the adjusted total daily insulin factor exceeds the maximum algorithm delivery threshold, which causes the process 100 to proceed to 150. At 150, the AP application or the AID algorithm executed by the processor may set the TDI for delivery of insulin to the user using the maximum algorithm daily threshold. In response, the AP application or AID algorithm at 150 may replace the adjusted total daily insulin factor with a predetermined total daily insulin factor, which may be, for example, 0.3-0.5 units/kilogram/day or the like. The AP application or the AID algorithm may calculate the set total daily insulin dosage using the predetermined total daily insulin factor and the weight of the user. For example, the AP application or the AID algorithm may set the TDI using the predetermined total daily insulin factor, which may be, example, 0.5 units/kilograms/day, in which case if the user weights 100 kg, the TDI is set to 50 units of insulin per day. 100 kg×0. units/kilograms/day. The actual TDI delivered may be dependent upon the inputted weight of the user. After setting the TDI either at 140 or 150, the process 100 proceeds to step 160. The device on which the AP application or AID algorithm is executing may be operable to establish communication links with other devices, such as a continuous glucose monitor (CGM) and a medical device, such as drug delivery device (shown in another example). For example, the processor of the device on which the AP application or AID algorithm is executing may be operable to generate a pairing request directed to a controller of a drug delivery device, a controller of a sensor or both. Based on a response to the pairing request from the processor, the processor of the device may establish a communication link with the controller or respective controllers. The control signal as well as other signals may be sent via the established communication link.

At step 160, the AP application or AID algorithm may output a control signal or control signals that control a drug delivery device (shown in another example) to begin administering insulin to the user based on the TDI setting from either 140 or 150. After beginning the outputting of the control signal(s) at step 160, the process 100 may proceed to 165. At 165, the AP application or the AID algorithm executed by the processor may begin collecting user blood glucose measurement values output by a continuous blood glucose monitor, also referred to as a continuous glucose monitor (CGM) (shown in another example). After a period of time of collecting the blood glucose measurement values of the user, the AP application or the AID algorithm executed by the processor may use the obtained blood glucose measurement values to calculate an attribute of the user's blood. For example, the AP application or AID algorithm may calculate, as a blood attribute, an Insulin-dose adjusted A1c (IDAA1c), or glycated hemoglobin value, for the user. In an example, IDAA1c is a model of insulin-dose adjusted glycated hemoglobin A1c, calculated as “A1c (%)+4× insulin dose (units per kilogram per 24 h (u/kg/24 hours)).” Alternatively, IDAA1c is defined as actual HbA1c+(4×insulin dose (u/kg/24 h)). If IDAA1c<9, the patient is in honeymoon phase and the patient partly depends on external insulin; otherwise IDAA1c>9, the patient is no longer able to produce insulin by themselves, they fully depend on external insulin.

The AP application or the AID algorithm may evaluate the calculated glycated hemoglobin (or IDAA1c) value at 170 with reference to a standard value indicative of a honeymoon threshold value of when the pancreas fails to produce sufficient insulin. In an example, the standard value for the blood attribute, such as IDAA1c, may be a honeymoon threshold value may be approximately 9. The honeymoon threshold value of approximately 9 may represent a percentage of the user's hemoglobin that is glycated hemoglobin. If a user's calculated amount of glycated hemoglobin is equal to or less than 9, the user may still be in the honeymoon period, also known as remission phase, while user's whose calculated glycated hemoglobin is greater than 9 may no longer be in the honeymoon period.

At 170, if the calculated glycated hemoglobin is determined by the AP application or the AID algorithm to be less than 9 (i.e., YES), which indicates the user is still in the honeymoon period, the process 100 may proceed back to 150. At 150, the AP application or the AID algorithm may set the TDI to the maximum daily insulin threshold and steps 160, 165 and 170 are repeated until the determination at 170 is NO, the user's glycated hemoglobin is no longer less than or equal to 9. In the response to the NO determining, the process 100 proceeds to 180. At 180, the AP application or the AID algorithm may increase the TDI setting because a honeymoon phase upper bound is unnecessary. The TDI setting may be the default setting, which may be above the maximum daily threshold value of 0.5 u/kg*weight, such as, for example, 0.53 u/kg. After increasing the TDI setting at 180, the AP application or the AID algorithm may generate and output control signals to the drug delivery device to actuate delivery of insulin according to the increased TDI setting (190).

In the example of FIG. 1 and as described above, the calculation of initial TDI for newly diagnosed users at steps 130, 140 and 150 may be encapsulated by the following formulation:

If 0.53u/kg * (1 − X) > 0.5u/kg:

TDI_initial= 0.5u/kg * weight (at block 150 of FIG. 1)

Else: TDI_initial= 0.53u/kg * (1 − X) * weight (at block 140 of FIG. 1).

In the example of FIG. 1, X can be defined as 50%, which may be determined based on a minimum value obtained from one or more cost functions as discussed above with reference to FIG. 4. If X is defined as 50% in the example, then the IF condition becomes redundant, and TDI_initialmay always be calculated by the ELSE condition.

In an alternate example, the initial TDI may be determined based on the user's weight and age. For example, when a starting TDI value is not available, the AID system can refer to the algorithm's predicted settings based on user's input weight and age to continue making insulin dosing decisions. This is predicated on the assumption that every newly-diagnosed user is in honeymoon phase, and the processes are intended to determine an optimal TDI reduction proportion to minimize the risk of both hyperglycemia and hypoglycemia for the newly-diagnosed user. FIG. 2 illustrates a flowchart of an alternative process. In the process 200, an AP application or an AID algorithm may receive a request to establish initial settings for an automatic insulin delivery device (210). In response to the received request, the AP application or AID algorithm may be operable to generate a graphical user interface and present the graphical user interface on a display device of a personal diabetes management device. The AP application or AID algorithm may receive an input of at least two physical characteristics of a user in response to the request. For example, the AP application or the AID algorithm may obtain a weight and an age of the user via the input (220). The use of a user's age may provide additional opportunities to optimize the user's total daily insulin dosage as teenagers may process insulin differently than an adult who is of the same weight because of the presence of more hormones in the teenagers.

In response to the received inputs, the AP application or AID algorithm may determine an adjusted total daily insulin factor that may be usable to calculate a total daily insulin dosage (230). For example, based on the inputted weight and age, the AP application or AID algorithm may access a lookup table of different ages and a value for a corresponding TDI per kilogram (kg).

The lookup table, for example, may be something like the table below that has a list of ages (2 years old to 24+years old) and a corresponding total daily insulin factor for each respective age. The table below as an example is available online at Researchgate.net as a publication entitled “Daily insulin requirement of children and adolescents . . . mode of therapy. Of course, other tables of data may be used or generated based on data from multiple user's, diabetes treatment organizations and research, or the like. In the table below, the total daily insulin factor may range from 0.61 (for individuals 4 years of age) to 0.80 (for individuals 14 and 15 years of age). It should be noted that the corresponding total daily insulin factors follow a bell shaped curve with a lowest value at age 2 (i.e., 0.62) to the highest factor values being at ages 14 and 15 (i.e., 0.80) to a factor value of 0.66 for those 24 years old and over.

Age
TDI/kg

2
0.62

3
0.64

4
0.61

5
0.66

6
0.66

7
0.68

8
0.68

9
0.73

10
0.72

11
0.73

12
0.77

13
0.79

14
0.80

15
0.80

16
0.78

17
0.76

18
0.73

19
0.74

20
0.69

21
0.66

22
0.69

23
0.69

24
0.66

24+
0.66

Upon determining the appropriate total daily insulin factor from the lookup table, the processor may generate an adjusted total daily insulin factor according to the following formula:

Adj. TDI Parameter=TDI/kg*weight in kg,

where (TDI/kg) is the total daily insulin factor, and XX is the reduction proportion.

The process may continue at 240, at which the AP application or AID algorithm may compare the determined adjusted total daily insulin factor to an upper bound for a maximum algorithm delivery threshold, which may be a value such as 0.5 u/kg (/day)(note here TDI or 0.5 is considered a per-day value, so the total daily insulin factor may be in units of u/kg or u/kg/day). The AP application or AID algorithm may generate a comparison result based on the comparison. In response to generating a comparison result by comparing the adjusted total daily insulin factor to a maximum algorithm delivery threshold, the AP application or AID algorithm may set a total daily insulin dosage based on the comparison result at 250. In a further example, in response to setting a total daily insulin dosage, the AP application or AID algorithm may output a control signal instructing a pump-mechanism controller to actuate a pump-mechanism to administer insulin according to the set total daily insulin dosage to begin delivering insulin to the user.

In another example, the personal diabetes management device, or the like, on which the AP application or AID algorithm is executing may be operable to establish communication links with other devices, such as a continuous glucose monitor (CGM) and a medical device, such as drug delivery device (shown in another example). For example, the processor of the device on which the AP application or AID algorithm is executing may be operable to generate a pairing request directed to a controller of a drug delivery device, a controller of a sensor, or both. Based on a response to the pairing request from the processor, the processor of the device may establish a communication link with the controller or respective controllers of a sensor and/or the drug delivery device. The control signal as well as other signals may be sent via the established communication link. Upon setting the total daily insulin dosage based on the comparison result, the AP application or AID algorithm may begin outputting a control signal or signals to a medical device or drug delivery device that instructs a controller of the respective device to actuate a pump to deliver insulin according to the present total daily insulin dosage setting.

In the example process 200, the AP application or AID algorithm may be operable to receive inputs, such as blood glucose measurement values from a continuous glucose monitor. For example, the processor of the personal diabetes management device may be communicatively coupled to the continuous glucose monitor. The AP application or AID algorithm may be operable to collect the user's blood glucose measurement values (260).

At 270, the AP application or AID algorithm may be operable to determine a level of an attribute of a user' blood based on the user's blood glucose measurement values. For example, the attribute of a user' blood may be an amount of glycated hemoglobin in the user's blood. Glycated hemoglobin also referred to insulin-dose adjusted glycated hemoglobin A1c (IDAA1c) as discussed with reference to the example of FIG. 1. At 270, the AP application or AID algorithm may determine whether the level of the attribute of the user's blood exceeds a threshold value or not. For example, the AP application or the AID algorithm may be operable to verify whether the user is in honeymoon phase or not. In response to the determined level of the blood attribute, the adjusted total daily insulin dosage may be modified to provide a modified total daily insulin dosage (280). The AP application or AID algorithm may be operable to generate a control signal including the modified total daily insulin dosage and output the control signal (290). In response to the outputted control signal, the processor may be operable to output the control signal in a wireless transmission to a pump-mechanism controller of a drug delivery device (described with reference to another example). The pump-mechanism controller may be operable to actuate delivery of insulin according to the modified total daily insulin dosage.

In the example of FIG. 2 and as described above, the setting of the initial TDI for newly diagnosed user based on the comparison result at step 250 may be encapsulated by the following formulation:

If TDI/kg * (1 − Y) > 0.5u/kg:

TDI_initial= 0.5u/kg * weight

Else:

TDI_initial= TDI/kg * (1 − Y) * weight

In the proposed example, the reduction proportion Y can be defined as 60% based on a minimum value obtained from one or more cost functions in a similar fashion as the selection of the 50% reduction proportion as discussed above with reference to FIG. 4. The reduction proportion may be determined using various methods. In a specific example, one or more cost functions may be defined to determine the reduction proportion of TDI per kg. The respective cost functions may be based on a high blood glucose index (HBGI) and a low blood glucose index (LBGI) that are selected to balance both hypoglycemic and hyperglycemic risk based on the expected overdose or underdose when utilizing the adjusted TDI factor versus actual clinical data (which may be used in an open-loop calculation or when a user is no longer considered “newly-diagnosed” (e.g., 6-18 months). In an example, the respective cost functions may be:

1) BGI_3h=Cost (accumulated insulin dose)=mean (HBGI or LBGI [3 hours out of 24 hours])
- 2) BGI_basal=Cost (basal insulin)=mean (HBGI or LBGI)
- 3) BGI_peak=Cost (insulin peak time)=mean (HBGI or LBGI [1.5 hours out of 24 hours])
  
  Where HBGI and LBGI may be calculated, for example, by the following logic:

LBGI = 0;

HBGI = 0;

CGM_new= 1.509 * ((log(CGM_current)){circumflex over ( )}1.084 − 5.381);

If CGM_current< 112.5 mg/dL:

LBGI = 10 * CGM_new{circumflex over ( )}2

Else:

HBGI = 10 * CGM_new{circumflex over ( )}2

Either HBGI or LBGI, in this example, remains at 0 depending on the value of the current glucose for which the risk is assessed. The non-zero value of either HBGI or LGBI may be utilized to calculate the cost.

FIG. 5 shows an example of results of the three cost functions suitable for use with the example processes of FIG. 2. FIG. 5 illustrates examples of 3 different cost functions. The top (or uppermost) cost function curve (labeled 510) is the BGI_3h cost function that may represent the cost of accumulated insulin doses and be based on an HGBI or LGBI over 3 hours out of 24 hours. From the curve 510 and table (middle) row 511, the BGI_3h cost function example has a minimum cost at approximately 23.93, which corresponds to an approximately 60% TDI reduction portion. The center cost function curve (labeled 520) is the BGI_basal cost function that may represent the cost of basal insulin doses and be based on a mean value of HGBI or LGBI. From the curve 520 and table (bottom) row 521, the BGI_basal cost function has a minimum cost at approximately 12.4, which corresponds to an approximately 60% TDI reduction portion. Meanwhile, the bottom (or lowest) cost function curve 530 is the BGI_peak cost function that may represent the cost of the occurrence of insulin peak time and be based on a mean value of HGBI or LGBI at approximately 1.5 hours after insulin delivery within a 24 hour period. From the curve 530 and table (top) row 531, the BGI_peak cost function has a minimum cost at approximately 8.79, which also corresponds to an approximate 55% TDI reduction portion. The table below the respective cost function curves includes a BGI_Peak row labeled 531, a BGI_3h row labeled 511, and a BGI_basal row labeled 521. Based on the output of the three cost functions, the TDI reduction proportion X may be selected to be approximately 60%. The approximately 60% value may be based on a mean value between the three cost functions (58.333%, which may round to 60%), a majority vote where 2 out of the 3 curves indicated a 60% TDI reduction proportion, or some other selection scheme or calculation (e.g., other than averaging and rounding) may be used. While the foregoing cost functions were explained in detail, other cost functions may be used as mentioned above with reference to FIGS. 1 and 4.

The described examples of FIGS. 1-5 provide an improved determination of TDI to optimize a newly-diagnosed user's diabetes treatment plan in a closed-loop system to further mitigate the chances of a hypoglycemic or hyperglycemic event.

In either process 100 of FIG. 1 or process 200 of FIG. 2, the AP application or AID algorithm may perform additional functions in response to the initial set up or onboarding request. For example, the AP application or AID algorithm may be operable to, in response to receipt of the request to establish initial settings for an automatic insulin delivery device, determine an availability of insulin history for the user.

In further alternate examples, different conditions may be used to determine the honeymoon period that may not be doctor-guided or based on a determination of an IDAA1c value (as in the foregoing examples) These different conditions may, for example, be used to build a classifier that predicts a honeymoon phase with gender, diabetic ketoacidosis (DKA) and other relative parameters, like a latest A1c value, as well as weight, age or both.

In further examples, the initial TDI estimates calculated according to the foregoing examples may be ignored after sufficient insulin delivery history is available, such as 48-72 hours of history based on a system that utilizes an AP application or an AID algorithm, and the insulin delivery history is the only component that is utilized for subsequent TDI calculations. For example, early in the processes 100 of FIGS. 1 and 200 of FIG. 2, the AP application or AID algorithm may perform additional functions. In an example, the AP application or AID algorithm may in response to receipt of the request to establish initial settings for an automatic insulin delivery device, determine an availability of an insulin history for the user. An insulin delivery history may include doses of insulin delivered, past TDI settings, blood glucose measurement values and the like. For example, the AP application or AID algorithm may communicate with a doctor or an automated system, such as server, that maintains diabetes-related records for the user (or the AP application or AID algorithm) to obtain a user's insulin delivery history. Alternatively, or in addition, the AP application or AID algorithm may query the user for information about a user's insulin delivery history. In response to the determination that the insulin delivery history for the user is unavailable, the AP application or AID algorithm may generate a prompt for the user to establish an initial setting for a total daily insulin dosage by inputting a weight of the user.

However, newly-diagnosed users, when determining insulin dosages on their own, may not deliver the correct amount of insulin needed to control their blood glucose. Therefore, the described examples calculate a starting TDI estimate that may be used as a component of the TDI estimate in the subsequent TDI calculations in addition to the TDI calculated from the insulin delivery history.

In the examples of FIGS. 1 and 2, the example processes may be implemented by programming code, such as an AP application or automatic insulin deliver (AID) application, that is executed by a processor. The AP application or the AID application when executed by a processor may utilize inputs and calculations as described with respect to the foregoing examples.

It may be helpful to discuss an example of a drug delivery system that may implement the process example of FIGS. 1 and 2. FIG. 3 illustrates an example of a drug delivery system suitable for implementing the example processes and techniques described herein including those described with reference to FIGS. 1 and 2. Details of an example of a personal diabetes management device operable to establish initial settings for an automatic insulin delivery device, which may be a wearable drug delivery device, a “pod,” such as an OmniPod® provided by Insulet Corp, or the like, are described with reference to the example system of FIG. 3.

The drug delivery system 300 may be operable to implement the process examples illustrated in FIGS. 1 and 2 by executing an AP application or an AID algorithm. In an operational example, the drug delivery system 300 may be operable to attain information associated with a user. The AP application or an AID algorithm may be operable to set an adjusted total daily insulin factor and determine whether the adjusted total daily insulin factor exceeds a maximum algorithm delivery threshold. In response to a result of the determination, set a total daily insulin dosage using the attained information; the AP application or AID algorithm may obtain blood glucose measurement values over a period of time. Based on the obtained blood glucose measurement values, a level of glycated hemoglobin of a user may be determined. The set total daily insulin dosage may be modified to provide a modified total daily insulin dosage in response to the determined level of glycated hemoglobin. The AP application or the AID algorithm may be operable to output a control signal including the modified total daily insulin dosage instructing a controller to actuate delivery of insulin according to the modified total daily insulin dosage.

The drug delivery system 300 may be an automatic drug delivery system that may include a medical device 302 (also referred to as “a drug delivery device” or “a wearable drug delivery device”), a blood glucose sensor 304 (also referred to as “a continuous glucose monitor” or “a blood glucose measurement device”), and a personal diabetes management (PDM) device 306. The system 300, in an example, may also include a smart device 307, which may be operable to communicate with the PDM 306 and other components of system 300 either via a wired or wireless communication link, such as 391, 392 or 393. In a specific example, the smart device 307 is coupled to the PDM 306 only via a wireless communication link 393, which may be a wireless communication link that utilizes the Bluetooth communication protocol or the like.

In an example, the medical device 302 may be attached to the body of a user, such as a patient or diabetic via, for example, an adhesive, and may deliver any therapeutic agent, including any drug or medicine, such as insulin, morphine or the like, to the user. The medical device 302 may, for example, be a wearable device worn by the user. For example, the medical device 302 may be directly coupled to a user (e.g., directly attached to a body part and/or skin of the user via an adhesive or the like). In an example, a surface of the medical device 302 may include an adhesive (not shown) to facilitate attachment to a user.

The medical device 302 may include a number of components to facilitate automatic delivery of a drug (also referred to as a therapeutic agent) to the user. The medical device 302 may be operable to store the drug (i.e., insulin) and to provide the drug to the user. The medical device 302 is often referred to as a pump, or an insulin pump, in reference to the operation of expelling insulin from the reservoir 325 for delivery to the user. While the examples refer to the reservoir 325 storing insulin, the reservoir 325 may be operable to store other drugs or therapeutic agents, such as morphine or the like, that are suitable for automatic delivery.

In various examples, the medical device 302 may be an automatic, wearable drug delivery device. For example, the medical device 302 may include a reservoir 325 for storing the drug (such as insulin), a needle or cannula (not shown) for delivering the drug into the body of the user (which may be done subcutaneously, intraperitoneally, or intravenously), and a pump mechanism (mech.) 324, or other drive mechanism, for transferring the drug from the reservoir 325, through a needle or cannula (not shown), and into the user. The pump mechanism 324 may be fluidly coupled to reservoir 325, and communicatively coupled to the medical device controller 321. The medical device 302 may also include a power source 328, such as a battery, a piezoelectric device, or the like, for supplying electrical power to the pump mechanism 324 and/or other components (such as the controller 321, memory 323, and the communication device 326) of the medical device 302. Although not shown, an electrical power supply for supplying electrical power may similarly be included in each of the sensor 304, the smart device 307 and the PDM device 306.

The blood glucose sensor 304 may be a device communicatively coupled to the PDM processor 361 or controller 321 and may be operable to measure a blood glucose value at a predetermined time interval, such as every 5 minutes, or the like. The blood glucose sensor 304 may provide a number of blood glucose measurement values to the AP applications (e.g., 329, 349, 369, or 379) operating on the respective devices (e.g., 302, 304, 306, or 307). While the AP applications 329, 349, 369 and 379 were discussed in detail and shown in the system 300 example of FIG. 3, the AP applications 329, 349, 369 and 379 may be replaced with an AID algorithm that is also operable to control and communicate with connected devices, such as medical device 302 and sensor 304, and manage a personal diabetes treatment program, and provide the functions and services as described herein.

The medical device 302 may provide the insulin stored in reservoir 325 to the user based on information (e.g., blood glucose measurement values, predicted future blood glucose measurements, evaluations based on a user request for a bolus, an user interaction with PDM 306, medical device 302, sensor 304 or smart device 307), evaluations of missing blood glucose measurements and the other information provided by the sensor 304, smart device 307, and/or the management device (PDM) 306. For example, the medical device 302 may contain analog and/or digital circuitry that may be implemented as a controller 321 for controlling the delivery of the drug or therapeutic agent. The circuitry used to implement the controller 321 may include discrete, specialized logic and/or components, an application-specific integrated circuit, a microcontroller or processor that executes software instructions, firmware, programming instructions or programming code (enabling, for example, the artificial pancreas application (AP App) 329 as well as the process examples of FIGS. 1 and 2) stored in memory 323, or any combination thereof. For example, the controller 321 may execute a control algorithm, such as the artificial pancreas application 329, and other programming code that may make the controller 321 operable to cause the pump to deliver doses of the drug or therapeutic agent to a user at predetermined intervals or as needed to bring blood glucose measurement values to a target blood glucose value. In an example, the AP application (App) 329 may include programming code that is operable upon execution by the controller 321 to provide the example processes for adjusting or modifying total daily insulin settings, or the like as described with reference to FIGS. 1 and 2. The user preferences for total daily insulin settings may be programmed, for example, into an artificial pancreas application 329 by the user or by a third party (such as a health care provider, medical device manufacturer, or the like) using a wired or wireless communication link, such as 331, between the medical device 302 and a personal diabetes management device 306 or other device, such as a computing device at a healthcare provider facility. In an example, the pump or medical device 302 is communicatively coupled to the PDM processor 361 of the personal diabetes management device via the wireless communication link 331 or via a wireless communication link, such as 391 from smart device 307 or 308 from the sensor 304. The pump mechanism 324 of the medical device 302 may be operable to receive an actuation signal from the PDM processor 361, and in response to receiving a command signal or an actuation signal, expel insulin from the reservoir 325 based on the commands from an AP application, such as 369.

In an operational example, the AP application 369 executing in the personal diabetes management device 306 may be operable to control delivery of insulin to a user. For example, the AP application 369 may be operable to determine timing of an insulin dose and may output a command signal to the medical device 302 that actuates the pump mechanism 324 to deliver an insulin dose. In addition, the AP application (or AID algorithm) 369 when loaded with programmed code that provides instructions for the functionality of FIGS. 1 and 2.

The other devices in the system 300, such as personal diabetes management device 306, smart device 307 and sensor 304, may also be operable to perform various functions including controlling the medical device 302. For example, the personal diabetes management device 306 may include a communication device 364, a PDM processor 361, and a personal diabetes management device memory 363. The personal diabetes management device memory 363 may store an instance of the AP application 369 that includes programming code, that when executed by the PDM processor 361 provides the process examples described with reference to the examples of FIGS. 1 and 2. The personal diabetes management device memory 363 may also store programming code for providing the process examples described with reference to the examples of FIGS. 1 and 2.

The smart device 307 may be, for example, a smart phone, an Apple Watch®, another wearable smart device, including eyeglasses, provided by other manufacturers, a global positioning system-enabled wearable, a wearable fitness device, smart clothing, or the like. Similar to the personal diabetes management device 306, the smart device 307 may also be operable to perform various functions including controlling the medical device 302. For example, the smart device 307 may include a communication device 374, a processor 371, and a memory 373. The memory 373 may store an instance of the AP application 379 and/or an instance of an AID application (not shown) that includes programming code for providing the process examples described with reference to the examples of FIGS. 2 and 3. The memory 373 may also as store programming code and be operable to store data related to the AP application 379 or an instance of an AID application (not shown). In an operational example, the AP application 379 may be operable to provide functionality similar to or the same the functionality as described with reference to the instance of the AP application 369.

The sensor 304 of system 300 may be a continuous glucose monitor (CGM) as described above, that may include a processor 341, a memory 343, a sensing or measuring device 344, and a communication device 346. The memory 343 may, for example, store an instance of an AP application 349 as well as other programming code and be operable to store data related to the AP application 349 and process examples described with reference to FIGS. 1 and 2. The AP application 349 may also include programming code for providing the process examples described with reference to the examples of FIGS. 1 and 2.

Instructions for determining the delivery of the drug or therapeutic agent (e.g., as a bolus dosage) to the user (e.g., the size and/or timing of any doses of the drug or therapeutic agent) may originate locally by the medical device 302 or may originate remotely and be provided to the medical device 302. In an example of a local determination of drug or therapeutic agent delivery, programming instructions, such as an instance of the artificial pancreas application 329, stored in the memory 323 that is coupled to the medical device 302 may be used to make determinations by the medical device 302. In addition, the medical device 302 may be operable to communicate with the cloud-based services 311 via the communication device 326 and the communication link 388. In an example, the system 300 may include one or more components operable to implement the process examples of FIGS. 1, 2, 4 and 5.

Alternatively, the remote instructions may be provided to the medical device 302 over a wired or wireless communication link (such as 331) by the personal diabetes management device (PDM) 306, which has a PDM processor 361 that executes an instance of the artificial pancreas application 369, or the smart device 307 (via communication link 391), which has a processor 371 that executes an instance of the artificial pancreas application 369 as well as other programming code for controlling various devices, such as the medical device 302, smart device 307 and/or sensor 304. In an example, the send a message to a server, for example, in the cloud services 311 or the like, requesting downloading of the one or more cost functions to a personal diabetes management (PDM) 306 or smart device 307. The medical device 302 may execute any received instructions (originating internally or from the personal diabetes management device 306) for the delivery of the drug or therapeutic agent to the user. In this way, the delivery of the drug or therapeutic agent to a user may be automatic.

In various examples, the medical device 302 may communicate via a wireless communication link 331 with the personal diabetes management device 306. The personal diabetes management device 306 may be an electronic device such as, for example, a smart phone, a tablet, a dedicated diabetes therapy personal diabetes management device, or the like. The personal diabetes management device 306 may be a wearable wireless accessory device. The wireless communication links 308, 331, 322, 391, 392 and 393 may be any type of wireless communication link provided by any known wireless standard. As an example, the wireless communication links 308, 331, 322, 391, 392 and 393 may enable communications between the medical device 302, the personal diabetes management device 306 and sensor 304 based on, for example, Bluetooth®, Wi-Fi®, a near-field communication standard, a cellular standard, or any other wireless optical or radio-frequency protocol.

The sensor 304 may be a glucose sensor operable to measure blood glucose and output a blood glucose value or data that is representative of a blood glucose value. For example, the sensor 304 may be a glucose monitor or a continuous glucose monitor (CGM). The sensor 304 may include a processor 341, a memory 343, a sensing/measuring device 344, and communication device 346. The communication device 346 of sensor 304 may include one or more sensing elements, an electronic transmitter, receiver, and/or transceiver for communicating with the personal diabetes management device 306 over a wireless communication link 322 or with medical device 302 over the link 308. The sensing/measuring device 344 may include one or more sensing elements, such as a glucose measurement, heart rate monitor, or the like. The processor 341 may include discrete, specialized logic and/or components, an application-specific integrated circuit, a microcontroller or processor that executes software instructions, firmware, programming instructions stored in memory (such as memory 343), or any combination thereof. For example, the memory 343 may store an instance of an AP application 349 that is executable by the processor 341.

Although the sensor 304 is depicted as separate from the medical device 302, in various examples, the sensor 304 and medical device 302 may be incorporated into the same unit. That is, in various examples, the sensor 304 may be a part of the medical device 302 and contained within the same housing of the medical device 302 (e.g., the sensor 304 may be positioned within or embedded within the medical device 302). Glucose monitoring data (e.g., measured blood glucose values) determined by the sensor 304 may be provided to the medical device 302, smart device 307 and/or the personal diabetes management device 306 and may be used to perform the functions and deliver doses of insulin for automatic delivery of insulin by the medical device 302 as described with reference to the examples of FIGS. 1 and 2.

The sensor 304 may also be coupled to the user by, for example, adhesive or the like and may provide information or data on one or more medical conditions and/or physical attributes of the user. The information or data provided by the sensor 304 may be used to adjust drug delivery operations of the medical device 302.

In an example, the personal diabetes management device 306 may be a mobile computing device operable to manage a personal diabetes treatment plan via an AP application or an AID algorithm. The personal diabetes management device 306 may be used to program or adjust operation of the medical device 302 and/or the sensor 304. The personal diabetes management device 306 may be any portable electronic, computing device including, for example, a dedicated controller, such as PDM processor 361, a smartphone, or a tablet. In an example, the personal diabetes management device (PDM) 306 may include a PDM processor 361, a personal diabetes management device memory 363, and a communication device 364. The personal diabetes management device 306 may contain analog and/or digital circuitry that may be implemented as a PDM processor 361 (or controller) for executing processes to manage a user's blood glucose levels and for controlling the delivery of the drug or therapeutic agent to the user. The PDM processor 361 may also be operable to execute programming code stored in the personal diabetes management device memory 363. For example, the personal diabetes management device memory 363 may be operable to store an artificial pancreas (AP) application 369 that may be executed by the PDM processor 361. The PDM processor 361 may when executing the artificial pancreas application 369 may be operable to perform various functions, such as those described with respect to the examples in FIGS. 1 and 2. The wireless communication device 364 may be a device, such as a receiver, a transmitter, or a transceiver that operates according to one or more radio-frequency protocols. For example, the communication device 364 may include a cellular transceiver and a Bluetooth transceiver that enables the personal diabetes management device 306 to communicate with a data network (not shown) via the cellular transceiver and with the sensor 304 and the medical device 302. The respective transceivers of communication device 364 may be operable to transmit signals containing information useable by or generated by the AP application or the like. The communication devices 326, 346 and 376 of respective medical device 302, sensor 304 and Smart device 307 may also be operable to transmit signals containing information useable by or generated by the AP application or the like.

The medical device 302 may communicate with the sensor 304 over a wireless communication link 308 and may communicate with the personal diabetes management device 306 over a wireless communication link 331. The sensor 304 and the personal diabetes management device 306 may communicate over a wireless communication link 322. The smart device 307, when present, may communicate with the medical device 302, the sensor 304 and the personal diabetes management device 306 over wireless communication links 391, 392 and 393, respectively. The wireless communication links 308, 331, 322, 391, 392 and 393 may be any type of wireless communication link operating using known wireless standards or proprietary standards. As an example, the wireless communication links 308, 331, 322, 391, 392 and 393 may provide communication links based on Bluetooth®, Wi-Fi, a near-field communication standard, a cellular standard, or any other wireless protocol via the respective communication devices 326, 346 and 364. In some examples, the medical device 302 and/or the personal diabetes management device 306 may include a user interface 327, 378 and 368, respectively, such as a keypad, a touchscreen display, levers, buttons, a microphone, a speaker, a light, a display, or the like, that is operable to allow a user to enter information and allow the personal diabetes management device to output information for presentation to the user. Note that the respective user interface devices 327, 378 and 368 may serve with the associated hardware, such as a touchscreen display, as both an input device and an output device. For example, the user interface devices may present graphical user interfaces that guide a user, for example, through the presentation of prompts, to input information or provide data to the user as well as other functions.

In various examples, the drug delivery system 300 may implement the artificial pancreas (AP) algorithm (and/or provide AP functionality) to govern or control automatic delivery of insulin to a user (e.g., to maintain euglycemia—a normal level of glucose in the blood). The AP application (or an AID algorithm) may be implemented by the medical device 302 and/or the sensor 304. The AP application may be operable to determine an initial total daily insulin dosage as described with reference to the examples of FIGS. 1, 2, 4 and 5, as well as the times and incremental dosages of insulin delivery. In various examples, the AP application (or the AID algorithm) may determine the times and dosages for delivery based on information known about the user, such as the user's sex, age, weight, or height, and/or on information gathered about a physical attribute or condition of the user (e.g., from the sensor 304). For example, the AP application may determine an appropriate delivery of insulin based on glucose level monitoring of the user through the sensor 304. The AP application may also allow the user to adjust insulin delivery. For example, the AP application may allow the user to issue (e.g., via an input) commands to the medical device 302, such as a command to deliver an insulin bolus. In some examples, different functions of the AP application may be distributed among two or more of the personal diabetes management device 306, the medical device 302 or the sensor 304. In other examples, the different functions of the AP application may be performed by one device, such the personal diabetes management device 306, the medical device 302 or the sensor 304.

As described herein, the drug delivery system 300 or any component thereof, such as the medical device may be considered to provide AP functionality or to implement an AP application. Accordingly, references to the AP application (e.g., functionality, operations, or capabilities thereof) are made for convenience and may refer to and/or include operations and/or functionalities of the drug delivery system 300 or any constituent component thereof (e.g., the medical device 302 and/or the personal diabetes management device 306). The drug delivery system 300—for example, as an insulin delivery system implementing an AP application—may be considered to be a drug delivery system or an AP application-based delivery system that uses sensor inputs (e.g., data collected by the sensor 304).

In an example, one or more of the devices, 302, 304, 306 or 307 may be operable to communicate via a wireless communication link 388 with cloud-based services 311. The cloud-based services 311 may utilize servers and data storage (not shown). The communication link 388 may be a cellular link, a Wi-Fi link, a Bluetooth link, or a combination thereof, that is established between the respective devices 302, 304, 306 or 307 of system 300. The data storage provided by the cloud-based services 311 may store insulin delivery history related to the user, cost function data related to general delivery of insulin to users, or the like. In addition, the cloud-based services 311 may process anonymized data from multiple users to provide generalized information related to the various parameters used by the AP application.

In an example, the device 302 includes a communication device 364, which as described above may be a receiver, a transmitter, or a transceiver that operates according to one or more radio-frequency protocols, such as Bluetooth, Wi-Fi, a near-field communication standard, a cellular standard, that may enable the respective device to communicate with the cloud-based services 311. For example, outputs from the sensor 304 or the medical device 302 may be transmitted to the cloud-based services 311 for storage or processing via the transceivers of communication device 364. Similarly, medical device 302, personal diabetes management device 306 and sensor 304 may be operable to communicate with the cloud-based services 311 via the communication link 388.

In an example, the respective receiver or transceiver of each respective device, 302, 306 or 307, may be operable to receive signals containing respective blood glucose measurement values of the number of blood glucose measurement values that may be transmitted by the sensor 304. The respective processor of each respective device 302, 306 or 307 may be operable to store each of the respective blood glucose measurement values in a respective memory, such as 323, 363 or 373. The respective blood glucose measurement values may be stored as data related to the artificial pancreas algorithm, such as 329, 349, 369 or 379. In a further example, the AP application operating on any of the personal diabetes management device 306, the Smart device 307, or sensor 304 may be operable to transmit, via a transceiver implemented by a respective communication device, 364, 374, 346, a control signal for receipt by a medical device. In the example, the control signal may indicate an amount of insulin to be expelled by the medical device 302.

Various operational scenarios and examples of processes performed by the system 300 are described herein. For example, the system 300 may be operable to implement the process examples of FIGS. 1 and 2.

The techniques described herein for providing functionality to set an adjusted total daily insulin factor and determine whether the adjusted total daily insulin factor exceeds a maximum algorithm delivery threshold. In response to a result of the determination, set a total daily insulin dosage using the attained information and obtain blood glucose measurement values over a period of time. Based on the obtained blood glucose measurement values, a level of glycated hemoglobin of a user may be determined. The set total daily insulin dosage may be modified to provide a modified total daily insulin dosage in response to the determined level of glycated hemoglobin. A control signal including the modified total daily insulin dosage may be output instructing a controller to actuate delivery of insulin according to the modified total daily insulin dosage.

For example, the system 300 or any component thereof may be implemented in hardware, software, or any combination thereof. Software related implementations of the techniques described herein may include, but are not limited to, firmware, application specific software, or any other type of computer readable instructions that may be executed by one or more processors. Hardware related implementations of the techniques described herein may include, but are not limited to, integrated circuits (ICs), application specific ICs (ASICs), field programmable arrays (FPGAs), and/or programmable logic devices (PLDs). In some examples, the techniques described herein, and/or any system or constituent component described herein may be implemented with a processor executing computer readable instructions stored on one or more memory components.

Some examples of the disclosed device may be implemented, for example, using a storage medium, a computer-readable medium, or an article of manufacture which may store an instruction or a set of instructions that, if executed by a machine (i.e., processor or microcontroller), may cause the machine to perform a method and/or operation in accordance with examples of the disclosure. Such a machine may include, for example, any suitable processing platform, computing platform, computing device, processing device, computing system, processing system, computer, processor, or the like, and may be implemented using any suitable combination of hardware and/or software. The computer-readable medium or article may include, for example, any suitable type of memory unit, memory, memory article, memory medium, storage device, storage article, storage medium and/or storage unit, for example, memory (including non-transitory memory), removable or non-removable media, erasable or non-erasable media, writeable or re-writeable media, digital or analog media, hard disk, floppy disk, Compact Disk Read Only Memory (CD-ROM), Compact Disk Recordable (CD-R), Compact Disk Rewriteable (CD-RW), optical disk, magnetic media, magneto-optical media, removable memory cards or disks, various types of Digital Versatile Disk (DVD), a tape, a cassette, or the like. The instructions may include any suitable type of code, such as source code, compiled code, interpreted code, executable code, static code, dynamic code, encrypted code, programming code, and the like, implemented using any suitable high-level, low-level, object-oriented, visual, compiled and/or interpreted programming language. The non-transitory computer readable medium embodied programming code may cause a processor when executing the programming code to perform functions, such as those described herein.

Certain examples of the present disclosure were described above. It is, however, expressly noted that the present disclosure is not limited to those examples, but rather the intention is that additions and modifications to what was expressly described herein are also included within the scope of the disclosed examples. Moreover, it is to be understood that the features of the various examples described herein were not mutually exclusive and may exist in various combinations and permutations, even if such combinations or permutations were not made express herein, without departing from the spirit and scope of the disclosed examples. In fact, variations, modifications, and other implementations of what was described herein will occur to those of ordinary skill in the art without departing from the spirit and the scope of the disclosed examples. As such, the disclosed examples are not to be defined only by the preceding illustrative description.

Program aspects of the technology may be thought of as “products” or “articles of manufacture” typically in the form of executable code and/or associated data that is carried on or embodied in a type of non-transitory, machine readable medium. Storage type media include any or all of the tangible memory of the computers, processors or the like, or associated modules thereof, such as various semiconductor memories, tape drives, disk drives and the like, which may provide non-transitory storage at any time for the software programming. It is emphasized that the Abstract of the Disclosure is provided to allow a reader to quickly ascertain the nature of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. In addition, in the foregoing Detailed Description, various features are grouped together in a single example for streamlining the disclosure. This method of disclosure is not to be interpreted as reflecting an intention that the claimed examples require more features than are expressly recited in each claim. Rather, as the following claims reflect, inventive subject matter lies in less than all features of a single disclosed example. Thus, the following claims are hereby incorporated into the Detailed Description, with each claim standing on its own as a separate example. In the appended claims, the terms “including” and “in which” are used as the plain-English equivalents of the respective terms “comprising” and “wherein,” respectively. Moreover, the terms “first,” “second,” “third,” and so forth, are used merely as labels and are not intended to impose numerical requirements on their objects.

The foregoing description of examples has been presented for the purposes of illustration and description. It is not intended to be exhaustive or to limit the present disclosure to the precise forms disclosed. Many modifications and variations are possible in light of this disclosure. It is intended that the scope of the present disclosure be limited not by this detailed description, but rather by the claims appended hereto. Future filed applications claiming priority to this application may claim the disclosed subject matter in a different manner and may generally include any set of one or more limitations as variously disclosed or otherwise demonstrated herein.

Claims

1. A non-transitory computer readable medium embodied with programming code executable by a processor, and the processor when executing the programming code is operable to perform functions, including functions to: receive a request via a graphical user interface to establish initial settings for an automatic insulin delivery device;receive an input of at least one physical characteristic of a user;determine an adjusted total daily insulin factor usable to calculate a total daily insulin dosage, wherein the adjusted total daily insulin factor is a total daily insulin per unit of a user's weight reduced by a reduction factor;generate a comparison result by comparing the adjusted total daily insulin factor to a maximum algorithm delivery threshold;based on the comparison result, set a total daily insulin dosage;obtain blood glucose measurement values over a period of time;based on the obtained blood glucose measurement values, determine a level of glycated hemoglobin of a user;in response to the determined level of glycated hemoglobin, modify the set total daily insulin dosage to provide a modified total daily insulin dosage; andoutput a control signal including the modified total daily insulin dosage instructing a controller of a drug delivery device to actuate delivery of insulin according to the modified total daily insulin dosage.
2. The non-transitory computer readable medium of claim 1, further embodied with programming code executable by the processor, and the processor when executing the programming code to set the total daily insulin dosage is further operable to perform functions, including functions to: determine that the comparison result indicates that the adjusted total daily insulin factor exceeds the maximum algorithm delivery threshold;replace the adjusted total daily insulin factor with a predetermined total daily insulin factor; andcalculate the set total daily insulin dosage using the predetermined total daily insulin factor and the weight of the user.
3. The non-transitory computer readable medium of claim 1, further embodied with programming code executable by the processor, and the processor when executing the programming code to set the total daily insulin dosage is further operable to perform functions, including functions to: determine that the comparison result indicates that the adjusted total daily insulin factor is less than the maximum algorithm delivery threshold; andcalculate the set total daily insulin dosage using the adjusted total daily insulin factor and the weight of the user.
4. The non-transitory computer readable medium of claim 1, further embodied with programming code executable by the processor, and the processor when executing the programming code is further operable to perform functions, including functions to: generate a pairing request directed to the controller of the drug delivery device; andbased on a response to the pairing request, establish a communication link with the controller, wherein the control signal is sent via the established communication link.
5. The non-transitory computer readable medium of claim 1, further embodied with programming code executable by the processor, and the processor when executing the programming code is further operable to perform functions, including functions to: in response to receipt of the request to establish initial settings for an automatic insulin delivery device, determine an availability of an insulin delivery history for the user; andin response to the insulin delivery history for the user being unavailable, generate a prompt for the user to establish an initial setting for a total daily insulin dosage by inputting a weight of the user.
6. The non-transitory computer readable medium of claim 1, further embodied with programming code executable by the processor, and the processor when executing the programming code is further operable to perform functions, including functions to: output a control signal instructing a controller of a drug delivery device to actuate a pump mechanism to administer insulin according to the set total daily insulin dosage.
7. The non-transitory computer readable medium of claim 1, further embodied with programming code executable by the processor, and the processor when executing the programming code is further operable to perform functions, including functions to: identify a reduction proportion of the adjusted total daily insulin factor, wherein the adjusted total daily insulin factor includes an insulin coefficient.
8. The non-transitory computer readable medium of claim 1, further embodied with programming code executable by the processor, and the processor, when determining an adjusted total daily insulin factor usable to calculate a total daily insulin dosage, executes the programming code to be further operable to perform functions, including functions to: evaluate the blood glucose measurement values with respect to one or more cost functions;based on the evaluation, determine a reduction proportion to be applied to the total daily insulin per unit of the user's weight; andapply the reduction proportion to the adjusted total daily insulin factor, wherein the reduction proportion reduces the set total daily insulin dosage.
9. The non-transitory computer readable medium of claim 8, further embodied with programming code executable by the processor, and the processor executes the programming code to be further operable to perform functions, including functions to: send a message, to a server, requesting downloading of the one or more cost functions to a personal diabetes management device.
10. The non-transitory computer readable medium of claim 1, further embodied with programming code executable by the processor, and the processor, when determining an adjusted total daily insulin factor usable to calculate a total daily insulin dosage, executes the programming code to be further operable to perform functions, including functions to:send a request to a server, wherein the request includes either an age of a user, a weight of the user, or both for input into one or more cost functions;receive a reduction proportion to be applied to the total daily insulin per unit of the user's weight, wherein the reduction proportion is based on the requested evaluation; and apply the reduction proportion to the adjusted total daily insulin factor, wherein the reduction proportion reduces the calculated set total daily insulin.
11. A device, comprising: a processor operable to execute programming code and applications;a memory coupled to the processor and operable to store programming code, an artificial pancreas application and data;a wireless communication device operable to wirelessly communicate with a paired device and communicatively coupled to the processor;wherein the artificial pancreas application is executable by the processor, wherein the processor, when executing the artificial pancreas application, is operable to perform functions, including functions to:attain information associated with a user;establish an adjusted total daily insulin factor;determine whether the adjusted total daily insulin factor exceeds a maximum algorithm delivery threshold;in response to a result of the determination, set a total daily insulin dosage using the attained information;obtain blood glucose measurement values over a period of time;based on the obtained blood glucose measurement values, determine a level of glycated hemoglobin of the user;in response to the determined level of glycated hemoglobin, modify the set total daily insulin dosage to provide a modified total daily insulin dosage; andoutput a control signal including the modified total daily insulin dosage instructing a controller to actuate delivery of insulin according to the modified total daily insulin dosage.
12. The device of claim 11, wherein the processor, when executing the artificial pancreas application, is further operable to perform functions, including functions to: determine that a comparison result indicates that the adjusted total daily insulin factor exceeds the maximum algorithm delivery threshold;replace the adjusted total daily insulin factor with a predetermined total daily insulin factor; andcalculate the set total daily insulin dosage using the predetermined total daily insulin factor and the attained information, wherein the attained information includes a weight of the user.
13. The device of claim 11, wherein the processor, when executing the artificial pancreas application, is further operable to perform functions, including functions to: determine that a comparison result indicates that the adjusted total daily insulin factor is less than the maximum algorithm delivery threshold; andcalculate the set total daily insulin dosage using the adjusted total daily insulin factor and the attained information, wherein the attained information includes a weight of the user.
14. The device of claim 11, wherein: the wireless communication device is operable to communicatively couple to a continuous blood glucose sensor,the processor operable to receive blood glucose measurement values via the wireless communication device from the continuous blood glucose sensor, andthe processor, when executing the artificial pancreas application, is further operable to perform functions, including functions to: generate a pairing request directed to a controller of a drug delivery device; andbased on a response to the pairing request, establish a communication link with the controller, wherein the control signal is sent via the established communication link.
15. The device of claim 11, wherein the processor, when executing the artificial pancreas application, is further operable to perform functions, including functions to: in response to receipt of the request to establish initial settings for an automatic insulin delivery device, determine an availability of an insulin delivery history for the user; andin response to the insulin delivery history for the user being unavailable, generate a prompt for the user to establish an initial setting for a total daily insulin dosage by inputting a weight of the user.
16. The device of claim 11, wherein the processor, when executing the artificial pancreas application, is further operable to perform functions, including functions to: output a control signal instructing a controller of a drug delivery device to actuate a pump mechanism to administer insulin according to the set total daily insulin dosage.
17. The device of claim 11, wherein the processor, when executing the artificial pancreas application, is further operable to perform functions, including functions to: store the attained information in the memory as data, wherein the attained information includes a weight of a user, an age of a user, or both.
18. The device of claim 11, wherein the processor, when executing the artificial pancreas application, is further operable to perform functions, including functions to: evaluate the blood glucose measurement values with respect to one or more cost functions;based on the evaluation, determine a reduction proportion to be applied to a total daily insulin per unit of a user's weight, wherein the attained information includes the user's weight; andapply the reduction proportion to the adjusted total daily insulin factor, wherein the reduction proportion reduces the calculated set total daily insulin.
19. The device of claim 18, wherein the processor, when executing the artificial pancreas application, is further operable to perform functions, including functions to: send a request, to a server, requesting the one or more cost functions; andin response to the request, receive the one or more cost function from the server.
20. The device of claim 11, wherein the processor, when executing the artificial pancreas application, is further operable to perform functions, including functions to: send a request to a server, wherein the request includes either an age of a user, a weight of the user, or both for input into one or more cost functions;receive a reduction proportion to be applied to a total daily insulin per unit of a user's weight, wherein the reduction proportion is based on a result of an evaluation performed in response to the request; andapply the reduction proportion to the adjusted total daily insulin factor, wherein the reduction proportion reduces the set total daily insulin dosage.

US Referenced Citations (587)

Number	Name	Date	Kind
303013	Horton	Aug 1884	A
2797149	Skeggs	Jun 1957	A
3631847	Hobbs	Jan 1972	A
3634039	Brondy	Jan 1972	A
3812843	Wootten et al.	May 1974	A
3841328	Jensen	Oct 1974	A
3963380	Thomas, Jr. et al.	Jun 1976	A
4055175	Clemens et al.	Oct 1977	A
4146029	Ellinwood, Jr.	Mar 1979	A
4151845	Clemens	May 1979	A
4245634	Albisser et al.	Jan 1981	A
4368980	Aldred et al.	Jan 1983	A
4373527	Fischell	Feb 1983	A
4403984	Ash et al.	Sep 1983	A
4464170	Clemens et al.	Aug 1984	A
4469481	Kobayashi	Sep 1984	A
4475901	Kraegen et al.	Oct 1984	A
4526568	Clemens et al.	Jul 1985	A
4526569	Bernardi	Jul 1985	A
4529401	Leslie et al.	Jul 1985	A
4559033	Stephen et al.	Dec 1985	A
4559037	Franetzki et al.	Dec 1985	A
4573968	Parker	Mar 1986	A
4624661	Arimond	Nov 1986	A
4633878	Bombardieri	Jan 1987	A
4657529	Prince et al.	Apr 1987	A
4685903	Cable et al.	Aug 1987	A
4731726	Allen, III	Mar 1988	A
4743243	Vaillancourt	May 1988	A
4755173	Konopka et al.	Jul 1988	A
4781688	Thoma et al.	Nov 1988	A
4781693	Martinez et al.	Nov 1988	A
4808161	Kamen	Feb 1989	A
4854170	Brimhall et al.	Aug 1989	A
4886499	Cirelli et al.	Dec 1989	A
4900292	Berry et al.	Feb 1990	A
4919596	Slate et al.	Apr 1990	A
4925444	Orkin et al.	May 1990	A
4940527	Kazlauskas et al.	Jul 1990	A
4975581	Robinson et al.	Dec 1990	A
4976720	Machold et al.	Dec 1990	A
4981140	Wyatt	Jan 1991	A
4994047	Walker et al.	Feb 1991	A
5007286	Malcolm et al.	Apr 1991	A
5097834	Skrabal	Mar 1992	A
5102406	Arnold	Apr 1992	A
5109850	Blanco et al.	May 1992	A
5125415	Bell	Jun 1992	A
5134079	Cusack et al.	Jul 1992	A
5153827	Coutre et al.	Oct 1992	A
5165406	Wong	Nov 1992	A
5176662	Bartholomew et al.	Jan 1993	A
5178609	Ishikawa	Jan 1993	A
5207642	Orkin et al.	May 1993	A
5232439	Campbell et al.	Aug 1993	A
5237993	Skrabal	Aug 1993	A
5244463	Cordner, Jr. et al.	Sep 1993	A
5257980	Van Antwerp et al.	Nov 1993	A
5273517	Barone et al.	Dec 1993	A
5281808	Kunkel	Jan 1994	A
5299571	Mastrototaro	Apr 1994	A
5308982	Ivaldi et al.	May 1994	A
5342298	Michaels et al.	Aug 1994	A
5377674	Kuestner	Jan 1995	A
5380665	Cusack et al.	Jan 1995	A
5385539	Maynard	Jan 1995	A
5389078	Zalesky	Feb 1995	A
5411889	Hoots et al.	May 1995	A
5421812	Langley et al.	Jun 1995	A
5468727	Phillips et al.	Nov 1995	A
5505709	Funderburk et al.	Apr 1996	A
5505828	Wong et al.	Apr 1996	A
5507288	Bocker et al.	Apr 1996	A
5533389	Kamen et al.	Jul 1996	A
5558640	Pfeiler et al.	Sep 1996	A
5569186	Lord et al.	Oct 1996	A
5584813	Livingston et al.	Dec 1996	A
5609572	Lang	Mar 1997	A
5665065	Colman et al.	Sep 1997	A
5678539	Schubert et al.	Oct 1997	A
5685844	Marttila	Nov 1997	A
5685859	Kornerup	Nov 1997	A
5693018	Kriesel et al.	Dec 1997	A
5697899	Hillman et al.	Dec 1997	A
5700695	Yassinzadeh et al.	Dec 1997	A
5703364	Rosenthal	Dec 1997	A
5714123	Sohrab	Feb 1998	A
5716343	Kriesel et al.	Feb 1998	A
5722397	Eppstein	Mar 1998	A
5741228	Lambrecht et al.	Apr 1998	A
5746217	Erickson et al.	May 1998	A
5755682	Knudson et al.	May 1998	A
5758643	Wong et al.	Jun 1998	A
5800405	McPhee	Sep 1998	A
5800420	Gross et al.	Sep 1998	A
5801057	Smart et al.	Sep 1998	A
5804048	Wong et al.	Sep 1998	A
5817007	Fodgaard et al.	Oct 1998	A
5820622	Gross et al.	Oct 1998	A
5823951	Messerschmidt	Oct 1998	A
5840020	Heinonen et al.	Nov 1998	A
5848991	Gross et al.	Dec 1998	A
5851197	Marano et al.	Dec 1998	A
5858005	Kriesel	Jan 1999	A
5865806	Howell	Feb 1999	A
5871470	McWha	Feb 1999	A
5879310	Sopp et al.	Mar 1999	A
5902253	Pfeiffer et al.	May 1999	A
5931814	Alex et al.	Aug 1999	A
5932175	Knute et al.	Aug 1999	A
5935099	Peterson et al.	Aug 1999	A
5947911	Wong et al.	Sep 1999	A
5971941	Simons et al.	Oct 1999	A
5993423	Choi	Nov 1999	A
5997501	Gross et al.	Dec 1999	A
6017318	Gauthier et al.	Jan 2000	A
6024539	Blomquist	Feb 2000	A
6032059	Henning et al.	Feb 2000	A
6036924	Simons et al.	Mar 2000	A
6040578	Malin et al.	Mar 2000	A
6049727	Crothall	Apr 2000	A
6050978	Orr et al.	Apr 2000	A
6058934	Sullivan	May 2000	A
6066103	Duchon et al.	May 2000	A
6071292	Makower et al.	Jun 2000	A
6072180	Kramer et al.	Jun 2000	A
6077055	Vilks	Jun 2000	A
6090092	Fowles et al.	Jul 2000	A
6101406	Hacker et al.	Aug 2000	A
6102872	Doneen et al.	Aug 2000	A
6115673	Malin et al.	Sep 2000	A
6123827	Wong et al.	Sep 2000	A
6124134	Stark	Sep 2000	A
6126637	Kriesel et al.	Oct 2000	A
6128519	Say	Oct 2000	A
6142939	Eppstein et al.	Nov 2000	A
6143164	Heller et al.	Nov 2000	A
6157041	Thomas et al.	Dec 2000	A
6161028	Braig et al.	Dec 2000	A
6162639	Douglas	Dec 2000	A
6196046	Braig et al.	Mar 2001	B1
6200287	Keller et al.	Mar 2001	B1
6200338	Solomon et al.	Mar 2001	B1
6214629	Freitag et al.	Apr 2001	B1
6226082	Roe	May 2001	B1
6244776	Wiley	Jun 2001	B1
6261065	Nayak et al.	Jul 2001	B1
6262798	Shepherd et al.	Jul 2001	B1
6270455	Brown	Aug 2001	B1
6271045	Douglas et al.	Aug 2001	B1
6280381	Malin et al.	Aug 2001	B1
6285448	Kuenstner	Sep 2001	B1
6309370	Haim et al.	Oct 2001	B1
6312888	Wong et al.	Nov 2001	B1
6334851	Hayes et al.	Jan 2002	B1
6375627	Mauze et al.	Apr 2002	B1
6379301	Worthington et al.	Apr 2002	B1
6402689	Scarantino et al.	Jun 2002	B1
6470279	Samsoondar	Oct 2002	B1
6475196	Vachon	Nov 2002	B1
6477901	Tadigadapa et al.	Nov 2002	B1
6484044	Lilienfeld-Toal	Nov 2002	B1
6491656	Morris	Dec 2002	B1
6512937	Blank et al.	Jan 2003	B2
6525509	Petersson et al.	Feb 2003	B1
6528809	Thomas et al.	Mar 2003	B1
6540672	Simonsen et al.	Apr 2003	B1
6544212	Galley et al.	Apr 2003	B2
6546268	Ishikawa et al.	Apr 2003	B1
6546269	Kurnik	Apr 2003	B1
6553841	Blouch	Apr 2003	B1
6554798	Mann et al.	Apr 2003	B1
6556850	Braig et al.	Apr 2003	B1
6558351	Steil et al.	May 2003	B1
6560471	Heller et al.	May 2003	B1
6561978	Conn et al.	May 2003	B1
6562001	Lebel et al.	May 2003	B2
6562014	Lin et al.	May 2003	B2
6569125	Jepson et al.	May 2003	B2
6572542	Houben et al.	Jun 2003	B1
6572545	Knobbe et al.	Jun 2003	B2
6574490	Abbink et al.	Jun 2003	B2
6575905	Knobbe et al.	Jun 2003	B2
6580934	Braig et al.	Jun 2003	B1
6618603	Varalli et al.	Sep 2003	B2
6633772	Ford et al.	Oct 2003	B2
6645142	Braig et al.	Nov 2003	B2
6653091	Dunn et al.	Nov 2003	B1
6662030	Khalil et al.	Dec 2003	B2
6669663	Thompson	Dec 2003	B1
6678542	Braig et al.	Jan 2004	B2
6699221	Vaillancourt	Mar 2004	B2
6718189	Rohrscheib et al.	Apr 2004	B2
6721582	Trepagnier et al.	Apr 2004	B2
6728560	Kollias et al.	Apr 2004	B2
6740059	Flaherty	May 2004	B2
6740072	Starkweather et al.	May 2004	B2
6751490	Esenaliev et al.	Jun 2004	B2
6758835	Close et al.	Jul 2004	B2
6780156	Haueter et al.	Aug 2004	B2
6810290	Lebel et al.	Oct 2004	B2
6837858	Cunningham et al.	Jan 2005	B2
6837988	Leong et al.	Jan 2005	B2
6846288	Nagar et al.	Jan 2005	B2
6862534	Sterling et al.	Mar 2005	B2
6865408	Abbink et al.	Mar 2005	B1
6890291	Robinson et al.	May 2005	B2
6936029	Mann et al.	Aug 2005	B2
6949081	Chance	Sep 2005	B1
6958809	Sterling et al.	Oct 2005	B2
6989891	Braig et al.	Jan 2006	B2
6990366	Say et al.	Jan 2006	B2
7008404	Nakajima	Mar 2006	B2
7009180	Sterling et al.	Mar 2006	B2
7016713	Gardner et al.	Mar 2006	B2
7018360	Flaherty et al.	Mar 2006	B2
7025743	Mann et al.	Apr 2006	B2
7025744	Utterberg et al.	Apr 2006	B2
7027848	Robinson et al.	Apr 2006	B2
7043288	Davis, III et al.	May 2006	B2
7060059	Keith et al.	Jun 2006	B2
7061593	Braig et al.	Jun 2006	B2
7096124	Sterling et al.	Aug 2006	B2
7115205	Robinson et al.	Oct 2006	B2
7128727	Flaherty et al.	Oct 2006	B2
7139593	Kavak et al.	Nov 2006	B2
7139598	Hull et al.	Nov 2006	B2
7144384	Gorman et al.	Dec 2006	B2
7171252	Scarantino et al.	Jan 2007	B1
7190988	Say et al.	Mar 2007	B2
7204823	Estes et al.	Apr 2007	B2
7248912	Gough et al.	Jul 2007	B2
7267665	Steil et al.	Sep 2007	B2
7271912	Sterling et al.	Sep 2007	B2
7278983	Ireland et al.	Oct 2007	B2
7291107	Hellwig et al.	Nov 2007	B2
7291497	Holmes et al.	Nov 2007	B2
7303549	Flaherty et al.	Dec 2007	B2
7303622	Loch et al.	Dec 2007	B2
7303922	Jeng et al.	Dec 2007	B2
7354420	Steil et al.	Apr 2008	B2
7388202	Sterling et al.	Jun 2008	B2
7402153	Steil et al.	Jul 2008	B2
7404796	Ginsberg	Jul 2008	B2
7429255	Thompson	Sep 2008	B2
7460130	Salganicoff	Dec 2008	B2
7481787	Gable et al.	Jan 2009	B2
7491187	Van Den Berghe et al.	Feb 2009	B2
7500949	Gottlieb et al.	Mar 2009	B2
7509156	Flanders	Mar 2009	B2
7547281	Hayes et al.	Jun 2009	B2
7569030	Lebel et al.	Aug 2009	B2
7608042	Goldberger et al.	Oct 2009	B2
7651845	Doyle, III et al.	Jan 2010	B2
7680529	Kroll	Mar 2010	B2
7734323	Blomquist et al.	Jun 2010	B2
7766829	Sloan et al.	Aug 2010	B2
7785258	Braig et al.	Aug 2010	B2
7806854	Damiano et al.	Oct 2010	B2
7806886	Kanderian, Jr.	Oct 2010	B2
7918825	OConnor et al.	Apr 2011	B2
7946985	Mastrototaro et al.	May 2011	B2
7972296	Braig et al.	Jul 2011	B2
8221345	Blomquist	Jul 2012	B2
8251907	Sterling et al.	Aug 2012	B2
8449524	Braig et al.	May 2013	B2
8452359	Rebec et al.	May 2013	B2
8454576	Mastrototaro et al.	Jun 2013	B2
8467980	Campbell et al.	Jun 2013	B2
8478557	Hayter et al.	Jul 2013	B2
8547239	Peatfield et al.	Oct 2013	B2
8597274	Sloan et al.	Dec 2013	B2
8622988	Hayter	Jan 2014	B2
8810394	Kalpin	Aug 2014	B2
9061097	Holt et al.	Jun 2015	B2
9171343	Fischell et al.	Oct 2015	B1
9233204	Booth et al.	Jan 2016	B2
9486571	Rosinko et al.	Nov 2016	B2
9579456	Budiman et al.	Feb 2017	B2
9743224	San Vicente et al.	Aug 2017	B2
9907515	Doyle, III et al.	Mar 2018	B2
9980140	Spencer et al.	May 2018	B1
9984773	Gondhalekar et al.	May 2018	B2
10248839	Levy et al.	Apr 2019	B2
10335464	Michelich	Jul 2019	B1
10583250	Mazlish et al.	Mar 2020	B2
10737024	Schmid	Aug 2020	B2
10987468	Mazlish et al.	Apr 2021	B2
11197964	Sjolund et al.	Dec 2021	B2
11260169	Estes	Mar 2022	B2
20010021803	Blank et al.	Sep 2001	A1
20010034023	Stanton, Jr. et al.	Oct 2001	A1
20010034502	Moberg et al.	Oct 2001	A1
20010051377	Hammer et al.	Dec 2001	A1
20010053895	Vaillancourt	Dec 2001	A1
20020010401	Bushmakin et al.	Jan 2002	A1
20020010423	Gross et al.	Jan 2002	A1
20020016568	Lebel et al.	Feb 2002	A1
20020040208	Flaherty et al.	Apr 2002	A1
20020123740	Flaherty et al.	Sep 2002	A1
20020128543	Leonhardt	Sep 2002	A1
20020147423	Burbank et al.	Oct 2002	A1
20020155425	Han et al.	Oct 2002	A1
20020161288	Shin et al.	Oct 2002	A1
20030023148	Lorenz et al.	Jan 2003	A1
20030050621	Lebel et al.	Mar 2003	A1
20030060692	Ruchti et al.	Mar 2003	A1
20030086074	Braig et al.	May 2003	A1
20030086075	Braig et al.	May 2003	A1
20030090649	Sterling et al.	May 2003	A1
20030100040	Bonnecaze et al.	May 2003	A1
20030130616	Steil et al.	Jul 2003	A1
20030135388	Martucci et al.	Jul 2003	A1
20030144582	Cohen et al.	Jul 2003	A1
20030163097	Fleury et al.	Aug 2003	A1
20030195404	Knobbe et al.	Oct 2003	A1
20030208113	Mault et al.	Nov 2003	A1
20030208154	Close et al.	Nov 2003	A1
20030212379	Bylund et al.	Nov 2003	A1
20030216627	Lorenz et al.	Nov 2003	A1
20030220605	Bowman, Jr. et al.	Nov 2003	A1
20040010207	Flaherty et al.	Jan 2004	A1
20040034295	Salganicoff	Feb 2004	A1
20040045879	Shults et al.	Mar 2004	A1
20040051368	Caputo et al.	Mar 2004	A1
20040064259	Haaland et al.	Apr 2004	A1
20040097796	Berman et al.	May 2004	A1
20040116847	Wall	Jun 2004	A1
20040122353	Shahmirian et al.	Jun 2004	A1
20040133166	Moberg et al.	Jul 2004	A1
20040147034	Gore et al.	Jul 2004	A1
20040171983	Sparks et al.	Sep 2004	A1
20040203357	Nassimi	Oct 2004	A1
20040204868	Maynard et al.	Oct 2004	A1
20040215492	Choi	Oct 2004	A1
20040220517	Starkweather et al.	Nov 2004	A1
20040241736	Hendee et al.	Dec 2004	A1
20040249308	Forssell	Dec 2004	A1
20050003470	Nelson et al.	Jan 2005	A1
20050020980	Inoue et al.	Jan 2005	A1
20050022274	Campbell et al.	Jan 2005	A1
20050033148	Haueter et al.	Feb 2005	A1
20050049179	Davidson	Mar 2005	A1
20050065464	Talbot et al.	Mar 2005	A1
20050065465	Lebel et al.	Mar 2005	A1
20050075624	Miesel	Apr 2005	A1
20050105095	Pesach et al.	May 2005	A1
20050137573	McLaughlin	Jun 2005	A1
20050171503	Van Den Berghe et al.	Aug 2005	A1
20050182306	Sloan	Aug 2005	A1
20050192494	Ginsberg	Sep 2005	A1
20050192557	Brauker et al.	Sep 2005	A1
20050197621	Poulsen et al.	Sep 2005	A1
20050203360	Brauker et al.	Sep 2005	A1
20050203461	Flaherty et al.	Sep 2005	A1
20050238507	Dilanni et al.	Oct 2005	A1
20050261660	Choi	Nov 2005	A1
20050272640	Doyle, III et al.	Dec 2005	A1
20050277912	John	Dec 2005	A1
20060009727	OMahony et al.	Jan 2006	A1
20060079809	Goldberger et al.	Apr 2006	A1
20060100494	Kroll	May 2006	A1
20060134323	OBrien	Jun 2006	A1
20060167350	Monfre et al.	Jul 2006	A1
20060173406	Hayes et al.	Aug 2006	A1
20060189925	Gable et al.	Aug 2006	A1
20060189926	Hall et al.	Aug 2006	A1
20060197015	Sterling et al.	Sep 2006	A1
20060200070	Callicoat et al.	Sep 2006	A1
20060204535	Johnson	Sep 2006	A1
20060229531	Goldberger et al.	Oct 2006	A1
20060253085	Geismar et al.	Nov 2006	A1
20060264895	Flanders	Nov 2006	A1
20060270983	Lord et al.	Nov 2006	A1
20060276771	Galley et al.	Dec 2006	A1
20060282290	Flaherty et al.	Dec 2006	A1
20070016127	Staib et al.	Jan 2007	A1
20070060796	Kim	Mar 2007	A1
20070060869	Tolle et al.	Mar 2007	A1
20070060872	Hall et al.	Mar 2007	A1
20070083160	Hall et al.	Apr 2007	A1
20070106135	Sloan et al.	May 2007	A1
20070116601	Patton	May 2007	A1
20070118405	Campbell et al.	May 2007	A1
20070129690	Rosenblatt et al.	Jun 2007	A1
20070142720	Ridder et al.	Jun 2007	A1
20070173761	Kanderian et al.	Jul 2007	A1
20070173974	Lin	Jul 2007	A1
20070179352	Randlov et al.	Aug 2007	A1
20070191716	Goldberger et al.	Aug 2007	A1
20070197163	Robertson	Aug 2007	A1
20070225675	Robinson et al.	Sep 2007	A1
20070244381	Robinson et al.	Oct 2007	A1
20070249007	Rosero	Oct 2007	A1
20070264707	Liederman et al.	Nov 2007	A1
20070282269	Carter et al.	Dec 2007	A1
20070287985	Estes et al.	Dec 2007	A1
20070293843	Ireland et al.	Dec 2007	A1
20080033272	Gough et al.	Feb 2008	A1
20080051764	Dent et al.	Feb 2008	A1
20080058625	McGarraugh et al.	Mar 2008	A1
20080065050	Sparks et al.	Mar 2008	A1
20080071157	McGarraugh et al.	Mar 2008	A1
20080071158	McGarraugh et al.	Mar 2008	A1
20080078400	Martens et al.	Apr 2008	A1
20080097289	Steil et al.	Apr 2008	A1
20080132880	Buchman	Jun 2008	A1
20080161664	Mastrototaro et al.	Jul 2008	A1
20080172026	Blomquist	Jul 2008	A1
20080177165	Blomquist et al.	Jul 2008	A1
20080188796	Steil et al.	Aug 2008	A1
20080200838	Goldberger et al.	Aug 2008	A1
20080206067	De Corral et al.	Aug 2008	A1
20080208113	Damiano et al.	Aug 2008	A1
20080214919	Harmon et al.	Sep 2008	A1
20080228056	Blomquist et al.	Sep 2008	A1
20080249386	Besterman et al.	Oct 2008	A1
20080269585	Ginsberg	Oct 2008	A1
20080269714	Mastrototaro et al.	Oct 2008	A1
20080269723	Mastrototaro et al.	Oct 2008	A1
20080287906	Burkholz et al.	Nov 2008	A1
20090006061	Thukral et al.	Jan 2009	A1
20090018406	Yodat et al.	Jan 2009	A1
20090030398	Yodat et al.	Jan 2009	A1
20090036753	King	Feb 2009	A1
20090043240	Robinson et al.	Feb 2009	A1
20090054753	Robinson et al.	Feb 2009	A1
20090069743	Krishnamoorthy et al.	Mar 2009	A1
20090069745	Estes et al.	Mar 2009	A1
20090069787	Estes et al.	Mar 2009	A1
20090099521	Gravesen et al.	Apr 2009	A1
20090105573	Malecha	Apr 2009	A1
20090131861	Braig et al.	May 2009	A1
20090156922	Goldberger et al.	Jun 2009	A1
20090156924	Shariati et al.	Jun 2009	A1
20090163781	Say et al.	Jun 2009	A1
20090198350	Thiele	Aug 2009	A1
20090221890	Saffer et al.	Sep 2009	A1
20090228214	Say et al.	Sep 2009	A1
20090318791	Kaastrup	Dec 2009	A1
20090326343	Gable et al.	Dec 2009	A1
20100057042	Hayter	Mar 2010	A1
20100114026	Karratt et al.	May 2010	A1
20100121170	Rule	May 2010	A1
20100137784	Cefai et al.	Jun 2010	A1
20100152658	Hanson et al.	Jun 2010	A1
20100174228	Buckingham et al.	Jul 2010	A1
20100211003	Sundar et al.	Aug 2010	A1
20100228110	Tsoukalis	Sep 2010	A1
20100262117	Magni et al.	Oct 2010	A1
20100262434	Shaya	Oct 2010	A1
20100295686	Sloan et al.	Nov 2010	A1
20100298765	Budiman et al.	Nov 2010	A1
20110021584	Berggren et al.	Jan 2011	A1
20110028817	Jin et al.	Feb 2011	A1
20110054390	Searle et al.	Mar 2011	A1
20110054399	Chong et al.	Mar 2011	A1
20110124996	Reinke et al.	May 2011	A1
20110144586	Michaud et al.	Jun 2011	A1
20110160652	Yodat et al.	Jun 2011	A1
20110178472	Cabiri	Jul 2011	A1
20110190694	Lanier, Jr. et al.	Aug 2011	A1
20110202005	Yodat et al.	Aug 2011	A1
20110218495	Remde	Sep 2011	A1
20110230833	Landman et al.	Sep 2011	A1
20110251509	Beyhan et al.	Oct 2011	A1
20110313680	Doyle et al.	Dec 2011	A1
20110316562	Cefai et al.	Dec 2011	A1
20120003935	Lydon et al.	Jan 2012	A1
20120010594	Holt et al.	Jan 2012	A1
20120030393	Ganesh et al.	Feb 2012	A1
20120053556	Lee	Mar 2012	A1
20120078067	Kovatchev et al.	Mar 2012	A1
20120078161	Masterson et al.	Mar 2012	A1
20120078181	Smith et al.	Mar 2012	A1
20120101451	Boit et al.	Apr 2012	A1
20120123234	Atlas et al.	May 2012	A1
20120136336	Mastrototaro et al.	May 2012	A1
20120190955	Rao et al.	Jul 2012	A1
20120203085	Rebec	Aug 2012	A1
20120203178	Tverskoy	Aug 2012	A1
20120215087	Cobelli et al.	Aug 2012	A1
20120225134	Komorowski	Sep 2012	A1
20120226259	Yodat et al.	Sep 2012	A1
20120232520	Sloan et al.	Sep 2012	A1
20120238851	Kamen et al.	Sep 2012	A1
20120271655	Knobel et al.	Oct 2012	A1
20120277668	Chawla et al.	Nov 2012	A1
20120282111	Nip et al.	Nov 2012	A1
20120295550	Wilson et al.	Nov 2012	A1
20130030358	Yodfat et al.	Jan 2013	A1
20130158503	Kanderian, Jr. et al.	Jun 2013	A1
20130178791	Javitt	Jul 2013	A1
20130231642	Doyle et al.	Sep 2013	A1
20130253472	Cabiri	Sep 2013	A1
20130261406	Rebec et al.	Oct 2013	A1
20130296823	Melker et al.	Nov 2013	A1
20130317753	Kamen et al.	Nov 2013	A1
20130338576	OConnor et al.	Dec 2013	A1
20140005633	Finan	Jan 2014	A1
20140066886	Roy et al.	Mar 2014	A1
20140074033	Sonderegger et al.	Mar 2014	A1
20140121635	Hayter	May 2014	A1
20140128839	Dilanni et al.	May 2014	A1
20140135880	Baumgartner et al.	May 2014	A1
20140146202	Boss et al.	May 2014	A1
20140180203	Budiman et al.	Jun 2014	A1
20140180240	Finan et al.	Jun 2014	A1
20140200426	Taub et al.	Jul 2014	A1
20140200559	Doyle et al.	Jul 2014	A1
20140230021	Birthwhistle et al.	Aug 2014	A1
20140276554	Finan et al.	Sep 2014	A1
20140276556	Saint et al.	Sep 2014	A1
20140278123	Prodhom et al.	Sep 2014	A1
20140309615	Mazlish	Oct 2014	A1
20140316379	Sonderegger et al.	Oct 2014	A1
20140325065	Birtwhistle et al.	Oct 2014	A1
20150018633	Kovachev et al.	Jan 2015	A1
20150025329	Amarasingham et al.	Jan 2015	A1
20150025495	Peyser	Jan 2015	A1
20150120317	Mayou et al.	Apr 2015	A1
20150134265	Kohlbrecher et al.	May 2015	A1
20150165119	Palerm et al.	Jun 2015	A1
20150173674	Hayes et al.	Jun 2015	A1
20150213217	Amarasingham et al.	Jul 2015	A1
20150217052	Keenan et al.	Aug 2015	A1
20150217053	Booth et al.	Aug 2015	A1
20150265767	Vazquez et al.	Sep 2015	A1
20150306314	Doyle et al.	Oct 2015	A1
20150351671	Vanslyke et al.	Dec 2015	A1
20150366945	Greene	Dec 2015	A1
20160015891	Papiorek	Jan 2016	A1
20160038673	Morales	Feb 2016	A1
20160038689	Lee et al.	Feb 2016	A1
20160051749	Istoc	Feb 2016	A1
20160082187	Schaible et al.	Mar 2016	A1
20160089494	Guerrini	Mar 2016	A1
20160175520	Palerm et al.	Jun 2016	A1
20160228641	Gescheit et al.	Aug 2016	A1
20160243318	Despa et al.	Aug 2016	A1
20160256087	Doyle et al.	Sep 2016	A1
20160287512	Cooper et al.	Oct 2016	A1
20160302054	Kimura et al.	Oct 2016	A1
20160331310	Kovatchev	Nov 2016	A1
20160354543	Cinar et al.	Dec 2016	A1
20170049386	Abraham et al.	Feb 2017	A1
20170143899	Gondhalekar et al.	May 2017	A1
20170143900	Rioux et al.	May 2017	A1
20170156682	Doyle et al.	Jun 2017	A1
20170173261	O'Connor et al.	Jun 2017	A1
20170189625	Cirillo et al.	Jul 2017	A1
20170281877	Marlin et al.	Oct 2017	A1
20170296746	Chen et al.	Oct 2017	A1
20170311903	Davis et al.	Nov 2017	A1
20170348482	Duke et al.	Dec 2017	A1
20180036495	Searle et al.	Feb 2018	A1
20180040255	Freeman et al.	Feb 2018	A1
20180075200	Davis et al.	Mar 2018	A1
20180075201	Davis et al.	Mar 2018	A1
20180075202	Davis et al.	Mar 2018	A1
20180092576	Ambrosio et al.	Apr 2018	A1
20180126073	Wu et al.	May 2018	A1
20180169334	Grosman et al.	Jun 2018	A1
20180200434	Mazlish et al.	Jul 2018	A1
20180200438	Mazlish et al.	Jul 2018	A1
20180200441	Desborough et al.	Jul 2018	A1
20180204636	Edwards et al.	Jul 2018	A1
20180277253	Gondhalekar et al.	Sep 2018	A1
20180289891	Finan et al.	Oct 2018	A1
20180296757	Finan	Oct 2018	A1
20180342317	Skirble et al.	Nov 2018	A1
20180369479	Hayter et al.	Dec 2018	A1
20190076600	Grosman et al.	Mar 2019	A1
20190240403	Palerm et al.	Aug 2019	A1
20190290844	Monirabbasi et al.	Sep 2019	A1
20190336683	O'Connor et al.	Nov 2019	A1
20190336684	O'Connor et al.	Nov 2019	A1
20190348157	Booth et al.	Nov 2019	A1
20200046268	Patek et al.	Feb 2020	A1
20200101222	Lintereur et al.	Apr 2020	A1
20200101223	Lintereur et al.	Apr 2020	A1
20200101225	O'Connor et al.	Apr 2020	A1
20200219625	Kahlbaugh	Jul 2020	A1
20200342974	Chen et al.	Oct 2020	A1
20210050085	Hayter et al.	Feb 2021	A1
20210098105	Lee et al.	Apr 2021	A1
20220023536	Graham	Jan 2022	A1

Foreign Referenced Citations (103)

Number	Date	Country
2015200834	Mar 2015	AU
2015301146	Mar 2017	AU
1297140	May 2001	CN
19756872	Jul 1999	DE
0341049	Nov 1989	EP
0496305	Jul 1992	EP
0549341	Jun 1993	EP
1491144	Dec 2004	EP
1571582	Sep 2005	EP
0801578	Jul 2006	EP
2666520	Oct 2009	EP
2139382	Jan 2010	EP
2397181	Dec 2011	EP
2695573	Feb 2014	EP
2830499	Feb 2015	EP
2943149	Nov 2015	EP
3177344	Jun 2017	EP
3314548	May 2018	EP
2897071	May 2019	EP
3607985	Feb 2020	EP
2443261	Apr 2008	GB
51125993	Nov 1976	JP
02131777	May 1990	JP
2004283378	Oct 2007	JP
2017525451	Sep 2017	JP
2018153569	Oct 2018	JP
2019525276	Sep 2019	JP
200740148	Oct 2007	TW
M452390	May 2013	TW
9800193	Jan 1998	WO
9956803	Nov 1999	WO
0030705	Jun 2000	WO
0032258	Jun 2000	WO
0172354	Oct 2001	WO
2002015954	Feb 2002	WO
0243866	Jun 2002	WO
02082990	Oct 2002	WO
03016882	Feb 2003	WO
03039362	May 2003	WO
03045233	Jun 2003	WO
2004043250	May 2004	WO
04092715	Oct 2004	WO
2005051170	Jun 2005	WO
2005082436	Sep 2005	WO
05110601	Nov 2005	WO
2005113036	Dec 2005	WO
2006053007	May 2006	WO
2007064835	Jun 2007	WO
2007078937	Jul 2007	WO
2008024810	Feb 2008	WO
2008029403	Mar 2008	WO
2008133702	Nov 2008	WO
2009045462	Apr 2009	WO
2009049252	Apr 2009	WO
2009066287	May 2009	WO
2009066288	May 2009	WO
2009098648	Aug 2009	WO
2009134380	Nov 2009	WO
2010053702	May 2010	WO
2010132077	Nov 2010	WO
2010138848	Dec 2010	WO
2010147659	Dec 2010	WO
2011095483	Aug 2011	WO
2012045667	Apr 2012	WO
2012108959	Aug 2012	WO
2012134588	Oct 2012	WO
2012177353	Dec 2012	WO
2012178134	Dec 2012	WO
2013078200	May 2013	WO
2013134486	Sep 2013	WO
20130149186	Oct 2013	WO
2013177565	Nov 2013	WO
2013182321	Dec 2013	WO
2014109898	Jul 2014	WO
2014110538	Jul 2014	WO
2014194183	Dec 2014	WO
2015056259	Apr 2015	WO
2015061493	Apr 2015	WO
2015073211	May 2015	WO
2015081337	Jun 2015	WO
2015187366	Dec 2015	WO
2016004088	Jan 2016	WO
2016022650	Feb 2016	WO
2016041873	Mar 2016	WO
2016089702	Jun 2016	WO
2016141082	Sep 2016	WO
2016161254	Oct 2016	WO
2017004278	Jan 2017	WO
2017091624	Jun 2017	WO
2017105600	Jun 2017	WO
2017184988	Oct 2017	WO
2017205816	Nov 2017	WO
2018009614	Jan 2018	WO
2018067748	Apr 2018	WO
2018120104	Jul 2018	WO
2018136799	Jul 2018	WO
2018204568	Nov 2018	WO
2019077482	Apr 2019	WO
2019094440	May 2019	WO
2019213493	Nov 2019	WO
2019246381	Dec 2019	WO
2020081393	Apr 2020	WO
2021011738	Jan 2021	WO

Non-Patent Literature Citations (103)

Entry
US 5,954,699 A, 09/1999, Jost et al. (withdrawn)
European Search Report for the European Patent Application No. 21168591.2, dated Oct. 13, 2021, 04 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2021/041954, dated Oct. 25, 2021, 13 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2021/047771, dated Dec. 22, 2021, 11 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2021/052855, dated Dec. 22, 2021, 11 pages.
Unger, Jeff, et al., “Glucose Control in the Hospitalized Patient,” Emerg. Med 36(9):12-18 (2004).
Glucommander FAQ downloaded from https://adaendo.com/GlucommanderFAQ.html on Mar. 16, 2009.
Finfer, Simon & Heritier, Stephane. (2009). The NICE-SUGAR (Normoglycaemia in Intensive Care Evaluation and Survival Using Glucose Algorithm Regulation) Study: statistical analysis plan. Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine. 11. 46-57.
Letters to the Editor regarding “Glucose Control in Critically Ill Patients,” N Engl J Med 361: 1, Jul. 2, 2009.
“Medtronic is Leading a Highly Attractive Growth Market,” Jun. 2, 2009.
Davidson, Paul C., et al. “Glucommander: An Adaptive, Computer-Directed System for IV Insulin Shown to be Safe, Simple, and Effective in 120,618 Hours of Operation,” Atlanta Diabetes Associates presentation Nov. 16, 2003.
Davidson, Paul C., et al. “Pumpmaster and Glucommander,” presented at the MiniMed Symposium, Atlanta GA, Dec. 13, 2003.
Kanji S., et al. “Reliability of point-of-care testing for glucose measurement in critically ill adults,” Critical Care Med, vol. 33, No. 12, pp. 2778-2785, 2005.
Krinsley James S., “Severe hypoglycemia in critically ill patients: Risk factors and outcomes,” Critical Care Med, vol. 35, No. 10, pp. 1-6, 2007.
European Patent Office, “Notification of Transmittal of the ISR and the Written Opinion of the International Searching Authority, or the Declaration,” in PCT Application No. PCT/GB2015/050248, dated Jun. 23, 2015, 12 pages.
Farkas et al. ““Single-Versus Triple-Lumen Central Catheter-Related Sepsis: A Prospective Randomized Study in a Critically Ill Population”” The American Journal of Medicine Sep. 1992vol. 93 p. 277-282.
Davidson, Paul C., et al., A computer-directed intravenous insulin system shown to be safe, simple,and effective in 120,618 h of operation, Diabetes Care, vol. 28, No. 10, Oct. 2005, pp. 2418-2423.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2021/016283, dated Jun. 2, 2021, 15 pages.
Gorke, A. “Microbial contamination of haemodialysis catheter connections.” EDTNA/ERCA journal (English ed.) vol. 31,2 (2005): 79-84. doi:10.1111/j.1755-6686.2005.tb00399.x.
Lovich et al. “Central venous catheter infusions: A laboratory model shows large differences in drug delivery dynamics related to catheter dead volume” Critical Care Med 2007 vol. 35, No. 12.
Van Den Berghe, Greet, M.D., Ph.D., et al., Intensive Insulin Therapy in Critically Ill Patients, The New England Journal of Medicine, vol. 345, No. 19, Nov. 8, 2001, pp. 1359-1367.
Templeton et al., “Multilumen Central Venous Catheters Increase Risk for Catheter-Related Bloodstream Infection: Prospective Surveillance Study” Infection 2008; 36: 322-327.
Wilson, George S., et al., Progress toward the Development of an Implantable Sensor for Glucose, Clin. Chem., vol. 38, No. 9, 1992, pp. 1613-1617.
Yeung et al. “Infection Rate for Single Lumen v Triple Lumen Subclavian Catheters” Infection Control and Hospital Epidemiology, vol. 9, No. 4 (Apr. 1988) pp. 154-158 The University of Chicago Press.
International Search Report and Written Opinion, International Application No. PCT/US2010/033794 dated Jul. 16, 2010 (OPTIS.247VPC).
International Search Report and Written Opinion in PCT/US2008/079641 (Optis.203VPC) dated Feb. 25, 2009.
Berger, ““Measurement of Analytes in Human Serum and Whole Blood Samples by Near-Infrared Raman Spectroscopy,”” Ph D. Thesis, Massachusetts Institute of Technology, Chapter 4, pp. 50-73, 1998.
Berger, “An Enhanced Algorithm for Linear Multivariate Calibration,” Analytical Chemistry, vol. 70, No. 3, pp. 623-627, Feb. 1, 1998.
Billman et. al.,“Clinical Performance of an In line Ex-Vivo Point of Care Monitor: A Multicenter Study,” Clinical Chemistry 48: 11, pp. 2030-2043, 2002.
Widness et al., “Clinical Performance on an In-Line Point-of-Care Monitor in Neonates”; Pediatrics, vol. 106, No. 3, pp. 497-504, Sep. 2000.
Finkielman et al., “Agreement Between Bedside Blood and Plasma Glucose Measurement in the ICU Setting”; retrieved from http://www.chestjournal.org; CHEST/127/5/May 2005.
Fogt, et al., “Development and Evaluation of a Glucose Analyzer for a Glucose-Controlled Insulin Infusion System (Biostator)”; Clinical Chemistry, vol. 24, No. 8, pp. 1366-1372, 1978.
Vonach et al., “Application of Mid-Infrared Transmission Spectrometry to the Direct Determination of Glucose in Whole Blood,” Applied Spectroscopy, vol. 52, No. 6, 1998, pp. 820-822.
Muniyappa et al., “Current Approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage,” AJP—Endocrinol Metab, vol. 294, E15-E26, first published Oct. 23, 2007.
R Anthony Shaw, et al., “Infrared Spectroscopy in Clinical and Dianostic Analysis,” Encyclopedia of Analytical Chemistry, ed. Robert A. Meyers, John Wiley & Sons, Ltd., pp. 1-20, 2000.
International Preliminary Report on Patentability for the International Patent Application No. PCT/US2019/053603, dated Apr. 8, 2021, 9 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2019/053603, dated Jan. 7, 2020, 16 pages.
Dassau et al., “Detection of a meal using continuous glucose monitoring: Implications for an artificial [beta]-cell.” Diabetes Care, American Diabetes Association, Alexandria, VA, US, 31(2):295-300 (2008).
Cameron et al., “Probabilistic Evolving Meal Detection and Estimation of Meal Total Glucose Appearance Author Affiliations”, J Diabetes Sci and Tech.vol., Diabetes Technology Society ;(5):1022-1030 (2009).
Lee et al., “A closed-loop artificial pancreas based on model predictive control: Human-friendly identification and automatic meal disturbance rejection”, Biomedical Signal Processing and Control, Elsevier, Amsterdam, NL, 4(4):1746-8094 (2009).
International Search Report and Written Opinion for the InternationalPatent Application No. PCT/US2021/018297, dated May 18, 2021, 18 pages.
An Emilia Fushimi: “Artificial Pancreas: Evaluating the ARG Algorithm Without Meal Announcement”, Journal of Diabetes Science and Technology Diabetes Technology Society, Mar. 22, 2019, pp. 1025-1043.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2021/017441, dated May 25, 2021, 12 pages.
International Search Report and Written Opinion for the InternationalPatent Application No. PCT/US2021/017664, dated May 26, 2021, 16 pages.
Mirko Messori et al: “Individualized model predictive control for the artificial pancreas: In silico evaluation of closed-loop glucose control”, IEEE Control Systems, vol. 38, No. 1, Feb. 1, 2018, pp. 86-104.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2021/017662, dated May 26, 2021, 14 pages.
Anonymous: “Reservoir Best Practice and Top Tips” Feb. 7, 2016, URL: https://www.medtronic-diabetes.co.uk/blog/reservoir-best-practice-and-top-tips, p. 1.
Gildon Bradford: “InPen Smart Insulin Pen System: Product Review and User Experience” Diabetes Spectrum, vol. 31, No. 4, Nov. 15, 2018, pp. 354-358.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2021/016050, dated May 27, 2021, 16 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2020/065226, dated May 31, 2021, 18 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2021/017659, dated May 31, 2021, 13 pages.
Montaser Eslam et al., “Seasonal Local Models for Glucose Prediction in Type 1 Diabetes”, IEE Journal of Biomedical and Health Informatics, IEEE, Piscataway, NJ, USA, vol. 24, No. 7, Jul. 2020, pp. 2064-2072.
Samadi Sediqeh et al., “Meal Detection and Carbohydrate Estimation Using Continuous Glucose Sensor Data” IEEE Journal of Biomedical and Health Informatics, IEEE, Piscataway, NJ, USA, vol. 21, No. 3, May 1, 2017, pp. 619-627.
Samadi Sediqeh et al., “Automatic Detection and Estimation of Unannouced Meals for Multivariable Artificial Pancreas System”, Diabetis Technology & Therapeutics, vol. 20m No. 3, Mar. 1, 2018, pp. 235-246.
Khodaei et al., “Physiological Closed-Loop Contol (PCLC) Systems: Review of a Modern Frontier in Automation”, IEEE Access, IEEE, USA, vol. 8, Jan. 20, 2020, pp. 23965-24005.
E. Atlas et al., “MD-Logic Artificial Pancreas System: A pilot study in adults with type 1 diabetes”, Diabetes Care, vol. 33, No. 5, Feb. 11, 2010, pp. 1071-1076.
Anonymous: “Fuzzy control system”, Wikipedia, Jan. 10, 2020. URL: https://en.wikipedia.org/w/index.php?title=Fuzzy_control_system&oldid=935091190.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2021/022694, dated Jun. 25, 2021, 13 pages.
International Search Report and Written Opinion for International Patent Application No. PCT/US2021/051027, dated Jan. 7, 2022, 16 pages.
International Search Report and Written Opinion for International Patent Application No. PCT/US2021/052372, dated Jan. 26, 2022, 15 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2021/046607, dated Jan. 31, 2022, 20 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2021/055745, dated Feb. 14, 2022, 13 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2020/052125, dated Aug. 12, 2020, 15 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2020/050332, dated Sep. 12, 2020, 12 pages.
International Search Report and Written Opinion for Application No. PCT/EP2019/060365, dated Aug. 13, 2019, 12 pages.
Anonymous: “Artificial pancreas—Wikipedia”, Mar. 13, 2018 (Mar. 13, 2018), XP055603712, Retrieved from the Internet: URL: https://en.wikipedia.org/wiki/Artificial_pancreas [retrieved on Jul. 9, 2019] section “Medical Equipment” and the figure labeled “The medical equipment approach to an artifical pancreas”.
Kaveh et al., “Blood Glucose Regulation via Double Loop Higher Order Sliding Mode Control and Multiple Sampling Rate.” Paper presented at the proceedings of the 17th IFAC World Congress, Seoul, Korea (Jul. 2008).
Dassau et al., “Real-Time Hypoglycemia Prediction Suite Using Contineous Glucose Monitoring,” Diabetes Care, vol. 33, No. 6, 1249-1254 (2010).
International Search Report and Written Opinion for International Patent Application No. PCT/US17/53262, dated Dec. 13, 2017, 8 pages.
Van Heusden et al., “Control-Relevant Models for Glucose Control using A Priori Patient Characteristics”, IEEE Transactions on Biomedical Engineering, vol. 59, No. 7, (Jul. 1, 2012) pp. 1839-1849.
Doyle III et al., “Run-to-Run Control Strategy for Diabetes Management.” Paper presented at 23rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society, Istanbul, Turkey (Oct. 2001).
Bequette, B.W., and Desemone, J., “Intelligent Dosing Systems”: Need for Design and Analysis Based on Control Theory, Diabetes Technology and Therapeutics 9(6): 868-873 (2004).
Parker et al., “A Model-Based Agorithm for Blood Gucose Control in Type 1 Diabetic Patients.” IEEE Transactions on Biomedical Engineering, 46 (2) 148-147 (1999).
International Search Report and Written Opinion for International Patent Application No. PCT/US2017/015601, dated May 16, 2017, 12 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2018/018901, dated Aug. 6, 2018, 12 pages.
International Search Report and Written Opinion for International Patent Application No. PCT/US2018/052467, dated Jan. 4, 2019, 13 pages.
“How to Create a QR Code that Deep Links to Your Mobile App”, Pure Oxygen Labs, web<https://pureoxygenlabs.com/how-to-create-a-qr-codes-that-deep-link-to-your-mobile-app/>. Year:2017.
“Read NFC Tags with an iPHone App on iOS 11”, GoToTags, Sep. 11, 2017, web <https://gototags.com/blog/read-nfc-tags-with-an-iphone-app-on-ios-11/>. (Year:2017).
International Search Report and Written Opinion for International Patent Application No. PCT/US2016/063350, dated Mar. 27, 2017, 9 pages.
Extended Search Report dated Aug. 13, 2018, issued in European Patent Application No. 16753053.4, 9 pages.
International Search Report and Written Opinion for International Patent Application No. PCT/US16/18452, dated Apr. 29, 2015, 9 pages.
International Preliminary Report on Patentability dated Aug. 31, 2017, issued in PCT Patent Application No. PCT/US2016/018452, 7 pages.
International Search Report and Written Opinion for International Patent Application No. PCT/US2019/055862, dated Mar. 11, 2020.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2022/013470, dated May 6, 2022, 14 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2022/013473, dated May 6, 2022, 13 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2022/019079, dated Jun. 2, 2022, 14 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2022/018453, dated Jun. 2, 2022, 13 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US22/018700, dated Jun. 7, 2022, 13 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US22/019080, dated Jun. 7, 2022, 14 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US22/019664, dated Jun. 7, 2022, 14 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US21/060618, dated Mar. 21, 2022, 15 pages.
Herrero Pau et al: “Enhancing automatic closed-loop glucose control in type 1 diabetes with an adaptive meal bolus calculator—in silicoevaluation under intra-day variability”, Computer Methods and Programs in Biomedicine, Elsevier, Amsterdam, NL, vol. 146, Jun. 1, 2017 (Jun. 1, 2017), pp. 125-131, XP085115607, ISSN: 0169-2607, DOI:10.1016/J.CMPB.2017.05.010.
Marie Aude Qemerais: “Preliminary Evaluation of a New Semi-Closed-Loop Insulin Therapy System over the prandial period in Adult Patients with type I diabetes: the WP6. 0 Diabeloop Study”, Journal of Diabetes Science and Technology Diabetes Technology Society Reprints and permissions, Jan. 1, 2014, pp. 1177-1184, Retrieved from the Internet: URL:http://journals.sagepub.com/doi/pdf/10.1177/1932296814545668 [retrieved on Jun. 6, 2022] chapter “Functioning of the Algorithm” chapter “Statistical Analysis” p. 1183, left-hand column, line 16-line 23.
Anonymous: “Kernel density estimation”, Wikipedia, Nov. 13, 2020 (Nov. 13, 2020), pp. 1-12, XP055895569, Retrieved from the Internet: URL:https://en.wikipedia.org/w/index.php?title=Kernel_density_estimation&oldid=988508333 [retrieved on Jun. 6, 2022].
Anonymous: “openaps / oref0 /lib/determine-basal-js”, openaps repository, Nov. 9, 2019 (Nov. 9, 2019), pp. 1-17, XP055900283, Retrieved from the Internet: URL:https://github.com/openaps/oref0/blob/master/lib/determine-basal/determine-basal [retrieved on Jun. 6, 2022] line 116-line 118, line 439-line 446.
Anonymous: “AndroidAPS screens”, AndroidAPS documentation, Oct. 4, 2020 (Oct. 4, 2020), pp. 1-12, XP055894824, Retrieved from the Internet: URL:https://github.com/openaps/AndroidAPSdocs/blob/25d8acf8b28262b411b34f416f173ac0814d7e14/docs/en/Getting-Started/Screenshots.md [retrieved on Jun. 6, 2022].
Kozak Milos et al: “Issue #2473 of AndroidAPS”, MilosKozak / AndroidAPS Public repository, Mar. 4, 2020 (Mar. 4, 2020), pp. 1-4, XP055900328, Retrieved from the Internet: URL:https://github.com/MilosKozak/AndroidAPS/Issues/2473 [retrieved on Jun. 6, 2022].
Medication Bar Code System Implementation Planning Section I: A Bar Code Primer for Leaders, Aug. 2013.
Medication Bar Code System Implementation Planning Section II: Building the Case for Automated Identification of Medications, Aug. 2013.
Villareal et al. (2009) in: Distr. Comp. Art. Intell. Bioninf. Soft Comp. Amb. Ass. Living; Int. Work Conf. Art. Neural Networks (IWANN) 2009, Leet. Notes Comp. Sci vol. 5518; S. Omatu et al. (Eds.), pp. 870-877.
Fox, Ian G.; Machine Learning for Physiological Time Series: Representing and Controlling Blood Glucose for Diabetes Management; University of Michigan. ProQuest Dissertations Publishing, 2020. 28240142. (Year: 2020).
International Search Report and Written Opinion for the International Patent Application No. PCT/US2022/012896, dated Apr. 22, 2022, 15 pages.
Glucon Critical Care Blood Glucose Monitor; Glucon; retrieved on Dec. 29, 2010 from http://www.glucon.com.

Related Publications (1)

	Number	Date	Country
	20210308377 A1	Oct 2021	US

Initial total daily insulin setting for user onboarding

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

CPC

International Classifications